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ABSTRACT 
 
Abnormally elevated postprandial glucose and triacylglycerol (TAG) concentrations are 
risk factors for cardiovascular disease in patients with type-2 diabetes. The most effective 
time to exercise to lower postprandial glucose and TAG concentrations is unknown. 
Thus, the aim of this study was to determine what time is more effective, either pre- or 
post-dinner resistance exercise (RE), at improving postprandial risk factors in patients 
with type-2 diabetes. Methods: Thirteen obese patients with type 2 diabetes completed 
three trials in a random order in which they consumed a standardized dinner meal with 1) 
no RE (NoRE), 2) pre-dinner RE (RE→M), and 3) post-dinner RE beginning 45 min 
after dinner (M→RE). During each trial blood samples were taken to measure glucose, 
TAG, acetaminophen (gastric emptying), endocrine responses, and mathematical 
modeling was used to asses beta-cell function. Indirect calorimetry was used to measure 
energy expenditure and substrate oxidation. A continuous glucose monitor was used to 
assess nocturnal and morning glycemic control the next day. A fasting blood sample was 
taken the following morning and the quantitative insulin sensitivity check index 
(QUICKI) was used to estimate whole body insulin sensitivity and the homeostatic model 
assessment of insulin resistance (HOMA-IR) was used as an estimate of hepatic insulin 
resistance. Results: The postprandial glucose iAUC was reduced (P < 0.05) by ~18% and 
30% during the RE→M and M→RE trials, respectfully, compared to NoRE, with no 
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difference between RE trials. The postprandial total TAG iAUC was ~92% lower (P < 
0.05) during M→RE compared to NoRE and RE→M, an effect due to lower VLDL-1 
TAG concentrations. RE→M and M→RE reduced the insulin iAUC by 35% and 48%, 
respectfully, compared to NoRE (P < 0.05), but via different mechanisms as RE→M 
enhanced insulin clearance, whereas M→RE reduced pancreatic insulin secretion and 
enhanced insulin clearance. The postprandial GLP-1 iAUC was ~49% lower (P < 0.05) 
during M→RE compared to NoRE and RE→M. Gastric emptying, beta-cell function, 
postprandial substrate oxidation, GIP, nocturnal and morning glycemic control, and the 
QUICKI and HOMA-IR index the next morning were not significantly different between 
trials (P > 0.05). Conclusions: Post-dinner RE improves metabolic risk factors more 
effectively than pre-dinner RE in obese patients with type 2 diabetes. However, the acute 
metabolic health benefits of RE are short-lived and do not extend into the overnight or 
morning period.  
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Figure 1. U.S. population trends with diagnosed diabetes [6].
CHAPTER 1 - INTRODUCTION 
Type 2 diabetes (T2D) is the most common form of diabetes mellitus and can be 
characterized by fasting and postprandial hyperglycemia. Clinically, T2D is diagnosed 
when an individual has a glycosylated hemoglobin (HbA1c) level ≥ 6.5%, a fasting 
plasma glucose ≥ 126 mg/dL (fasting defined as no caloric intake for at least 8 h), or a 
plasma glucose ≥ 200 mg/dL at 2 h post an oral glucose tolerance test (Table 1).    
Table 1. Clinical criteria for normal, pre-diabetic, and diabetic individuals.  
 HbA1c (%) 
Fasting Plasma Glucose 
(mg/dL) 
Two-hour Oral Glucose 
Tolerance Test (mg/dL) 
Diabetes ≥ 6.5 ≥ 126 ≥ 200 
Pre-Diabetes 5.7 to 6.4 100 to 125 140 to 199 
Normal ≤ 5.6 ≤ 99 ≤ 139 
Source: [1] 
 The prevalence of T2D is increasing in the U.S. [2-3] and developed nations 
around the world [4-5]. In the U.S., over 21 million Americans (~7% of the population) 
have been diagnosed with diabetes [6] (Figure 1).  
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According to the World Health Organization, diabetes is the 7th leading cause of 
death in developed nations [7]. In addition, T2D provokes the development of several 
other diseases including vascular (macro and micro) disease (the leading cause of death 
in developed nations), stroke, hypertension, blindness, kidney disease, nervous system 
disease, and if untreated can lead to amputations [8]. In addition, the health care costs of 
treating T2D and its co-morbidities are staggering and place a heavy burden on 
healthcare budgets [9-12]. Thus, it is critical that effective therapies be identified that 
prevent or treat T2D. In the treatment of T2D, the main goal is to increase insulin 
sensitivity and attenuate hyperglycemia and hypertriacylglyceridemia, which can be 
accomplished with bariatric surgery, pharmacologically, and/or with lifestyle 
intervention. In particular, exercise is effective at improving metabolic control in 
individuals with T2D, and thus is a cornerstone in the treatment of T2D.  
Exercise Guidelines for Type 2 Diabetics 
Numerous studies show that aerobic exercise (AE) training, resistance exercise 
(RE) training, or a combination of both improves glycemic control or prevents glycemic 
control from worsening in individuals with T2D [13-31]. Further, combination training 
has been shown to be more effective than either one alone in improving glycemic control 
[13-14]. Thus, the current exercise guidelines for individuals with T2D provided by the 
American College of Sports Medicine and American Diabetes Association state 
individuals with T2D should partake in at least 150 min/week of moderate to vigorous 
AE spread out over 3 d per week and engage in moderate to vigorous RE at least 2–3 d 
per week [32-34]. Although acute exercise or exercise training generally improves 
glycemic and lipemic control, inter-individual variability is large as there is considerable 
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heterogeneity in responses [35-37], and there are even a couple of studies demonstrating 
a single session of exercise has no significant impact on glycemic [38-39] or lipemic [37, 
40] control in individuals with T2D. It is not completely clear why some individuals are 
“exercise sensitive” and have beneficial changes in glycemia and/or lipemia with exercise 
and some individuals are “exercise insensitive” and do not experience improvements or 
have a worsening of glycemic or lipemic control with exercise. Possible explanations for 
this phenomenon after exercise training could be genetic factors [41] or baseline (pre-
training) fasting blood glucose concentrations [42-43]. Following an acute session of 
exercise, a lack of change in glycemia with exercise has been related to HbA1c, such that 
individuals with a greater HbA1c (thus higher glucose concentrations) have bigger 
improvements in glycemic control following an acute AE session, whereas individuals 
with more tightly controlled glycemic control (lower HbA1c concentrations) have less of 
an improvement [36]. In another study, an acute session of AE prior to a meal did not 
result in a significant change in postprandial TAG concentrations on average, but there 
was tremendous inter-individual variability in the response with some individuals having 
improvements, while others had no improvement or the postprandial TAG response 
increased. Interestingly, in this study the postprandial TAG response was related to the 
propensity to increase hepatic fatty acid oxidation following AE, such that individuals 
that had greater increases in hepatic fatty acid oxidation following AE had lower 
postprandial TAG concentrations [37]. Another possibility that has been overlooked is 
the timing of exercise around a meal. An unexamined hypothesis is that, and in the 
context of acute exercise, some individuals are exercise insensitive (non-responders) 
because they are exercising at an inappropriate time relative to a meal, and that moving 
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the exercise session from before a meal to after a meal may perhaps make an individual 
exercise sensitive (responder). Currently, the exercise guidelines for individuals with 
T2D only include the recommended mode, dosage, frequency, and intensity, but do not 
include any information on the best time to exercise, particularly relative to the last meal 
(before or after), to improve metabolic risk factors including postprandial glucose and 
TAG concentrations. With a push toward personalized medicine, an understanding of the 
best time to exercise to improve glycemic and lipemic control is warranted so that more 
effective exercise prescriptions can be made.     
Exercise Timing and Postprandial Glycemia and Lipemia in Type 2 Diabetics 
The few studies that have directly examined how exercise timing impacts 
glycemic and lipemic control are acute exercise studies utilizing AE. The first series of 
studies highlighting the potential importance of exercise timing were done by Poirier and 
colleagues [44-46]. In one study, capillary blood glucose was measured before and after 1 
h of moderate intensity cycling (60% of VO2max) either in the fasted state or after a meal 
(within 5 h). Exercise in the fasting state did not change blood glucose levels, whereas 
post-meal exercise within 5 h of the last meal reduced blood glucose considerably 
(between 28-43% decrease) [45]. Using a similar study design, Gaudet-Savard et al. [44] 
showed that exercise in the fasted state resulted in variable changes in blood glucose 
depending on the pre-exercise glucose level such that individuals with pre-exercise blood 
glucose levels < 6 mmol/l would experience an increase in blood glucose during exercise, 
while individuals with pre-exercise blood glucose levels > 6 mmol/l would experience no 
change or a decrease in blood glucose during exercise. On the contrary, the response was 
more uniform with post-meal exercise, as exercise in the fed state reduced blood glucose 
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concentrations in all individuals regardless of the pre-exercise blood glucose level, 
although the glucose lowering effect of exercise was more pronounced in individuals 
with higher blood glucose concentrations. In addition, post-meal exercise lowered blood 
glucose the most when performed within 5 h of the last meal. A limitation of these 
studies is the lack of stringent dietary control, blood glucose was only measured before 
and after exercise, and there was no direct comparison of pre-meal vs. post-meal exercise. 
In a more carefully controlled study, 1 h of moderate intensity AE (60% of VO2max) 
performed after breakfast in the lab (starting 2 h after breakfast) lowered blood glucose 
concentrations more so than exercise in the fasted state [46]. This study is limited 
because there was no direct comparison of pre-meal vs. post-meal exercise on 
postprandial glucose responses. To my knowledge, the only study to directly compare the 
effect of pre-meal AE against post-meal AE was done by Colberg et al. [47], and they 
found that 20 min of self-paced treadmill walking performed 20 min after a dinner meal 
significantly lowered postprandial blood glucose concentrations, but the same bout of 
exercise performed prior to dinner had no effect on postprandial blood glucose 
concentrations. Taken together, these data indicate that post-meal AE has more of a 
beneficial impact on postprandial glycemia than postabsorptive AE in individuals with 
T2D.  
Only three studies have examined the impact of acute AE on postprandial 
triacylglycerol (TAG) concentrations in individuals with T2D. In two of the studies [37, 
40], the AE bout was performed the day prior to the test meal given, and these studies 
reported that on average prior AE had no effect on postprandial TAG concentrations, 
compared to a no exercise trial, although the response was highly variable. Interestingly, 
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in another study the AE bout was performed starting 90 min after a high fat breakfast 
meal, and in this study the exercise bout significantly reduced the average postprandial 
TAG response in individuals with T2D [48]. Although no study has directly compared 
pre-meal exercise to post-meal exercise, the available research suggests that the timing of 
AE around a meal might be critical in lowering postprandial TAG concentrations. It is 
possible that changing exercise timing from pre-meal to post-meal may make an 
individual more exercise sensitive, although this hypothesis has never been examined.  
The aforementioned studies cited examined AE, but no study has examined how 
resistance exercise (RE) timing relative to dinner alters postprandial glycemia and 
lipemia. From a practical perspective many obese type 2 diabetic patients may not enjoy 
AE or be motivated to perform AE soon after a meal, but RE may be a practical 
alternative and may be preferred over AE in some obese individuals because traditional 
RE is performed with the person sitting or lying down and there are short work periods 
with long rests between sets. However, compared to AE, RE is a very different 
physiological stimulus (i.e. RE is anaerobic, does not involve continuous skeletal muscle 
contractions, and has lower energy expenditure), thus it is not clear if RE would improve 
postprandial glycemia and lipemia as robustly as AE. Some studies report acute RE prior 
to a meal improves glycemic control [49-50], while other studies report it does not [38], 
and no study has assessed how acute RE alters postprandial TAG concentrations. In 
addition, these studies assessed the effects of RE on postprandial glycemia and lipemia 
after a breakfast or lunch meal, and not a dinner meal later in the day, a time when 
postprandial glucose and TAG concentrations have been reported to be highest in 
individuals with T2D [51-52]. Thus, more research is needed to validate RE as an 
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effective means to improve postprandial glucose and TAG concentrations. Further, the 
best time to perform RE in obese patients with T2D needs to be established. Knowledge 
of the best time to perform RE will help health care professionals design more 
personalized exercise programs that maximize the metabolic benefits of exercise. This 
information is of clinical interest and will provide translational knowledge that can be 
used to make better exercise prescriptions and exercise guidelines for individuals with 
T2D.   
Why Might Post-meal Exercise Be Better at Improving Glycemic and Lipemic 
Control? 
 
There are several potential mechanisms explaining why post-meal exercise may 
be superior at lowering postprandial glucose than pre-meal exercise in individuals with 
T2D. Although both pre- and post-meal exercise may increase skeletal muscle glucose 
uptake, post-meal exercise may increase skeletal muscle glucose uptake more. This 
premise is supported by studies by Larsen et al. [53-54] that illustrated that compared to a 
no exercise trial, moderate or high intensity AE performed 45 min after a breakfast meal 
increased the rate of disappearance of the infused tracer 3-[3H]-glucose (labeling 
endogenous glucose) without altering its rate of appearance. In addition, the postprandial 
glucose response to a subsequent lunch meal was unaltered in this study, which further 
supports the concept that post-meal exercise is better compared to pre-meal exercise at 
lowering postprandial glucose concentrations. Since individuals with T2D (non-insulin 
dependent) have some insulin secretion [53-54], it is feasible that post-meal exercise 
increases skeletal muscle glucose uptake to a greater extent compared to pre-meal 
exercise because of the synergistic effect of insulin and skeletal muscle contractions on 
increasing skeletal muscle glucose uptake in addition to insulin suppressing endogenous 
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glucose output from the liver. After ingestion of a mixed meal, the insulin/glucagon ratio 
increases, which results in two simultaneous effects including 1) attenuated hepatic 
glucose output [55] and 2)  increases in skeletal muscle blood flow and capillary 
recruitment [56], glucose transporter type 4 (GLUT-4) translocation [57], and blood 
glucose uptake [58]. Although these processes are impaired in individuals with T2D, the 
effect of insulin on skeletal muscle blood glucose uptake is enhanced by skeletal muscle 
contractions, as data has shown insulin [57] and muscle contractions [57, 59] 
independently increase skeletal muscle GLUT-4 translocation and blood glucose uptake, 
and when combined synergistically increase skeletal muscle GLUT-4 translocation 
and/or blood glucose uptake to a greater extent than either one alone in humans [57] and 
rodents [60-61]. Thus, postprandial exercise in the face of increasing insulin 
concentrations with a prior meal should synergistically increase skeletal muscle blood 
glucose uptake and suppress hepatic glucose output, and result in lower postprandial 
blood glucose compared to pre-meal exercise. 
Additionally, reduced gastric emptying may work in conjunction with increased 
skeletal muscle blood glucose uptake and reduced hepatic glucose output to lower 
postprandial blood glucose concentrations with post-meal exercise, but not with pre-meal 
exercise. Prior research has shown that postprandial AE augments the postprandial 
glucagon-like peptide-1 (GLP-1) response in healthy individuals, an effect that was 
associated with lower blood glucose concentrations [62]. One function of GLP-1 is to 
inhibit gastric emptying [63-65]. High intensity AE has been shown to reduce gastric 
emptying of a carbohydrate solution in healthy men [66-67], thus it is possible that the 
reduced gastric emptying caused by higher intensity AE is mediated by higher GLP-1 
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concentrations (although this has never been examined experimentally). The effect that 
RE has on GLP-1 or gastric emptying in individuals with T2D is unknown. However, it is 
plausible that post-meal RE would augment postprandial GLP-1 concentrations, and this 
would be associated with reduced gastric emptying and reduced glucagon concentrations 
(as GLP-1 has also been shown to inhibit glucagon release from the pancreas), an effect 
that will not be present with pre-meal RE. Ultimately, a reduced rate of gastric emptying 
will reduce glucose delivery to the intestine, which will reduce glucose dependent 
insulinotropic polypeptide (GIP) secretion from the intestine, and glucose uptake into the 
blood stream, thereby resulting in lower postprandial blood glucose, insulin, and c-
peptide concentrations with post-meal RE compared to pre-meal RE.  
The available research suggests that post-meal AE reduces postprandial TAG 
concentrations [48], while pre-meal AE does not in patients with type 2 diabetes [37, 40]. 
This effect may be mediated by the interplay of a couple of different mechanisms 
involving increased clearance of TAG and/or reduced secretion of TAG. During post-
meal exercise, circulating free fatty acid concentrations are low (because the meal 
increases insulin concentrations, and insulin reduces lipolysis) so there may not be 
enough free fatty acids to supply the increase in skeletal muscle fatty acid oxidation 
induced by exercise, thus more TAG are hydrolyzed so that free fatty acids from TAG 
can be liberated and taken up from the blood by the exercising skeletal muscle. In 
addition, post-meal exercise likely increases skeletal muscle blood flow, which increases 
blood flow through previously non-flowing capillaries, allowing more TAG to be 
exposed to lipoprotein lipase (enzyme that hydrolyzes TAG to glycerol and free fatty 
acids) which would produce more widespread hydrolysis of TAG.  
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Another possibility is that post-meal exercise reduces endogenous and exogenous 
TAG secretion. Post-meal exercise may reduce gastric emptying, which will slow the 
digestion and absorption of dietary fatty acids and thus reduce the secretion of exogenous 
chylomicron TAG from the intestine. It is also possible post-meal exercise reduces 
endogenous very-low density lipoprotein TAG (VLDL-TAG) secretion from the liver 
perhaps by changing gut blood flow, hormones/metabolites concentrations delivered to 
the liver, or neural input to the liver. All of these mechanisms are speculative and warrant 
further investigation.       
Acute Resistance Exercise and Nocturnal and Fasting Blood Glucose 
Although many individuals with T2D spend the majority of their day in the 
postprandial state during the day, a significant portion of their day is during the overnight 
period, and the lowering of nocturnal blood glucose concentrations is of clinical interest 
and an important component in the treatment of T2D. Only two studies have directly 
examined how acute RE impacts nocturnal blood glucose concentrations, and both 
studies used continuous glucose monitoring (CGM) technology. van Dijk et al. [50] 
reported that an acute bout of RE in the morning prior to lunch reduced the prevalence of 
nocturnal (12 – 6 a.m.) hyperglycemia (defined as time spent with blood glucose > 180 
mg/dL) the following night but did not significantly alter the average glucose 
concentration [50]. In contrast, Bacchi et al. [39] reported that an acute bout of RE at 
night prior to dinner (~6:30 p.m.) did not alter nocturnal (1–5 a.m.) average blood 
glucose concentrations. In addition, some [49, 68], but not all [69] research has 
demonstrated that acute RE does not improve insulin sensitivity or lowers fasting blood 
glucose concentrations the next morning in individuals with T2D or impaired fasting 
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blood glucose concentrations. Based on the majority of these studies, it appears that pre-
meal exercise prior to lunch or dinner does not alter subsequent nocturnal blood glucose 
concentrations or insulin sensitivity the next day. It is not known if performing RE after 
dinner, a time that is closer to the nocturnal period, would have a more significant impact 
on lowering nocturnal blood glucose concentrations.  
Summary  
In summary, T2D places a large burden on an individual’s health and well-being 
in addition to the health care system [9-12], and thus cost friendly and effective treatment 
strategies are needed to reduce these burdens. Overall, exercise improves glycemic and 
lipemic control in individuals with T2D, but most studies show great variability in the 
response with some individuals being exercise sensitive (i.e. have improvements in 
glycemic and lipemic control with acute exercise, responders) while others are exercise 
insensitive (i.e. do not have improvements in glycemic or lipemic control with acute 
exercise, non-responders) [35-37]. It is possible that some individuals are not sensitive to 
exercise because they are exercising at an inappropriate time, but the most optimal time 
to exercise is not clear. Although limited, some data suggests that post-meal AE is more 
beneficial at improving postprandial glucose and TAG concentrations than pre-meal AE 
in individuals with T2D [47-48]. The superior effect of post-meal AE on lowering 
postprandial blood glucose and TAG concentrations may be partially mediated by 
reduced gastric emptying and gut blood flow, although the relationship between different 
exercise times and changes in gastric emptying and postprandial glycemia and lipemia 
has never been studied. The impact that RE timing (pre-meal RE vs. post-meal RE) has 
on postprandial or nocturnal glycemic or lipemic control in individuals with T2D has 
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never been studied. Obese individuals with T2D may not enjoy AE or be motivated to 
perform AE soon after a meal, thus RE is an alternative option and may be preferred over 
AE in obese individuals. Compared to AE, RE is a very different physiological stimulus 
(i.e. RE is anaerobic, recruits more type II skeletal muscle fibers, and is not continuous), 
thus it is not clear if post-meal RE would improve postprandial glucose and TAG 
concentrations as robustly as AE. Further, little research has examined how a single RE 
session alters glycemic control in individuals with T2D, and the data are mixed as some 
studies report RE improves glycemic control in individuals with T2D [49-50] while other 
studies report it does not [38]. No study has assessed how a single session of RE alters 
postprandial TAG concentrations in individuals with T2D. Therefore, more research is 
needed to validate RE as an effective means to improve metabolic control in the evening 
and examine how RE timing relative to a dinner meal impacts post-meal metabolic 
control to identify the best time to exercise in obese individuals with T2D. Knowledge of 
the best time to exercise will allow health care practitioners to make more effective 
exercise prescriptions that maximize the metabolic benefits of RE and reduce exercise 
non-responders.        
Specific Aims, Hypotheses, Delimitations, Significance, and Innovation 
The overarching goal of this dissertation project was to determine if performing 
RE after a meal is better at improving metabolic control (possibly by reducing gastric 
emptying), compared to pre-meal RE, in individuals with T2D. Importantly, another goal 
of this project was to determine how the different RE times altered subjective well-being 
(pleasure) to determine how feasible each RE time is (i.e. did the participants actually 
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enjoy exercising before or after they ate compared to not exercising). The specific aims 
of this project are: 
Specific Aim 1: To determine if post-dinner RE is more effective compared to pre-dinner 
RE at improving postprandial glucose and TAG concentrations. 
Aim 1a: To determine if alterations in pancreatic (insulin, c-peptide, and glucagon) and 
gut (glucose-dependent insulinotropic polypeptide and glucagon-like peptide-one) 
hormone concentrations, whole body substrate oxidation, gastric emptying, free fatty 
acids, and beta-cell function are related to RE induced changes in postprandial glucose 
and TAG concentrations.    
Hypothesis: Post-dinner RE beginning 45 min after a dinner meal, compared to pre-
dinner RE ending ~30 min prior to a dinner meal, will result in lower 4 h postprandial 
glucose, TAG, insulin, c-peptide, GIP, free fatty acids, and gastric emptying responses 
but a greater GLP-1 response and enhanced beta-cell function in individuals with T2D. 
The originally proposed 4 h postprandial responses are illustrated in Table 2.  
Specific Aim 2: To determine if post-dinner RE is more effective compared to pre-dinner 
RE at lowering nocturnal (12 – 6 a.m.) blood glucose concentrations, fasting morning 
blood glucose concentrations, and postprandial blood glucose concentrations to a 
standardized breakfast meal the next morning. 
Hypothesis: Post-meal RE will be more effective compared to pre-dinner RE at 
improving nocturnal blood glucose concentrations and fasting and postprandial glucose 
concentrations the next morning because post-meal RE will be performed closer to when 
these measurements are taken. 
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Stomach
Organ No Exercise Pre-meal RE Post-meal RE
Intestine
Liver
Muscle
Pancreas
↓ Gastric Emptying
↑↑ Glucose Output
↓ Gastric Emptying ↓↓ Gastric Emptying
↑↑ Glucose Output ↑ Glucose Output
↑ GLP-1
↑↑ GIP
↑ GLP-1
↑↑ GIP
↑↑ GLP-1
↑ GIP
↑ Glucose Uptake ↑ Glucose Uptake ↑ Glucose Uptake
↓ Glucose Output ↓ Glucose Output ↓ Glucose Output
↑ Glucose Uptake ↑ Glucose Uptake ↑↑ Glucose Uptake
↑↑ Insulin ↑ Insulin ↑ Insulin
↑↑ c-peptide ↑ c-peptide ↑ c-peptide
↔ Glucagon ↔ Glucagon ↔ Glucagon
↓ Well-being (Pleasure)Brain
↓↓ Beta Cell Function ↑ Beta Cell Function ↑↑ Beta Cell Function
↑↑ Well-being (Pleasure) ↑↑ Well-being (Pleasure)
Specific Aim 3: To determine how RE timing impacts subjective well-being (pleasure). 
Hypothesis: Subjective well-being will be greater when RE is performed compared to no 
exercise, independent of its timing. 
Table 2. Hypothesized 4 h postprandial responses during each trial.  
 
 
 
 
 
 
 
 
 
 
 
Significance and Innovation 
For the first time, this study examined if post-dinner RE is superior compared to 
pre-dinner RE at improving postprandial risk factors in individuals with T2D both in a 
lab setting and under free-living conditions outside of the lab. These findings have direct 
translational application for exercise prescription for individuals with T2D, as knowledge 
of how different RE times relative to a meal impacts risk factors and insulin sensitivity 
will allow more effective exercise prescriptions to be made that will maximize the 
metabolic benefits of RE. 
15	
	
CHAPTER 2 - EXPERIMENTAL DESIGN AND METHODS 
Participants 
The University of Missouri Health Science Institutional Review Board approved 
this study protocol and all participants provided written informed consent. All 
participants included in this study were obese (defined as body mass index > 30 kg/m2 
and body fat > 22%, assessed via the BOD POD®), physician diagnosed with type 2 
diabetes, receiving standard medical care, non-smokers, not using insulin, had no history 
of surgery for weight loss, refrained from performing exercise or going on any special 
diets while participating, and were weight stable while participating in this study. The 
participants were instructed to take their medications at the usual dose, frequency, and 
time and not to change this routine while participating in this study.  
General Study Design 
Prior to beginning the study, all participants performed baseline testing which 
included measuring resting energy expenditure and free-living physical activity energy 
expenditure, strength testing, and two familiarization sessions (described in detail later). 
Following this, each participant performed three different, 3 d trials (counterbalanced 
design, participants serve as their own controls) in a random order. 
The study design is illustrated in Figure 2 (page 18). 
Specific Aim 1: To determine if post-dinner RE is more effective compared to pre-dinner 
RE at improving postprandial glucose and TAG concentrations. 
Aim 1a: To determine if alterations in pancreatic (insulin, c-peptide, and glucagon) and 
gut (glucose-dependent insulinotropic polypeptide and glucagon-like peptide-one) 
hormone concentrations, whole body substrate oxidation, gastric emptying, free fatty 
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acids, and beta-cell function are related to RE induced changes in postprandial glucose 
and TAG concentrations.    
For Specific Aim 1, the participants completed three different ~6 h trials in our 
Exercise Physiology Lab. Each trial started between 3 – 5:30 p.m. (depending on the 
participants schedule), and upon arrival for each trial a venous catheter was inserted into 
the forearm of the participant. Blood samples were taken every 5 or 10 min during the 
first 4 h while in the lab, and then every 30 min during the last 2 h in the lab until the end 
of testing (~9 - 11:30 p.m.). Sometime between 5 – 7 p.m. (depending on arrival) the 
participants began eating a standardized dinner meal and were given 20 min to eat the 
meal. During the no RE trial (NoRE), the participants remained sedentary during testing. 
During the pre-dinner RE trial (RE→M), ~45 min of RE was performed prior to dinner 
(ending ~20-30 min prior to dinner). During the post-dinner RE trial (M→RE), ~45 min 
of RE was performed beginning 45 min after finishing the meal. During the M→RE trial, 
the RE session began 45 min after dinner because we wanted the participants to finish the 
RE session prior to the postprandial glucose peak (which in our lab in well controlled 
T2D is ~1 h and 15 min after ingestion of a mixed meal) and prior to the contents of the 
meal being emptied from the stomach. Thus, the RE session would attenuate the blood 
glucose response to the meal to a greater extent than waiting longer after the meal. 
Acetaminophen was ingested with the dinner meal, and was used to indirectly assess 
gastric emptying. In addition to blood sampling, indirect calorimetry was used to measure 
energy expenditure and whole body substrate oxidation and subjective well-being 
measurements were taken after each blood draw for ~6 h while the participants were in 
the lab (more specific details of these measurements are described later). After the last 
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blood sample was taken the participants were released from the lab and allowed to 
resume normal daily activities and sleep in their own home.  
Specific Aim 2: To determine if post-dinner RE is more effective compared to pre-dinner 
RE at lowering nocturnal (12 – 6 a.m.) blood glucose concentrations, fasting morning 
blood glucose concentrations, and postprandial blood glucose concentrations to a 
standardized breakfast meal the next morning. 
For Specific Aim 2, a continuous glucose monitor system (CGMS) was utilized to 
assess glucose concentrations under free-living conditions during the overnight period 
and to a standardized breakfast meal the morning after testing in the lab. During the 
evening of day one, the participants reported to the lab and the CGMS was inserted and 
the participants were trained on how to take and record a finger stick blood glucose 
measure. Following training, the participants were given their prepackaged study meals 
and instructed on when to eat the meals. On day two, the participants ate the prepackaged 
meals at the scheduled times on their own in the morning and afternoon. The evening 
meal was eaten in the lab while testing for Specific Aim 1 was occurring. Prior to the 
breakfast and lunch meal on day 2, the participants took and recorded a finger stick blood 
glucose measure, which was used to calibrate the CGMS. On day three of all trials, the 
participants reported to the lab in the morning after an overnight fast and a fasting blood 
sample was taken, and they were then given a standardized breakfast meal. The CGMS 
was used to measure the 4 h postprandial blood glucose response after breakfast.  
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NoRE Trial
Day 1 Day 2 Day 3
Insert 
CGMS Meal MealMeal
6-8 a.m. 11-1 p.m. 5-7 p.m.
Meal
6-9 a.m.
Remove
CGMS
11-1 p.m.6 p.m.
RE→M Trial
M→RE Trial
Nocturnal 
Glucose 
Analysis
Blood
Samples
Fasting Sample
Sedentary
RE
RE
Indirect 
Calorimetry
Subjective 
Well-being Post
Breakfast 
Glucose 
Analysis
Aim 1 and 3 Aim 2
Specific Aim 3: To determine how resistance exercise timing impacts subjective well-
being (pleasure). 
 For Specific Aim 3, a visual analog scale was used to assess the subjective well-
being of each subject while testing in the lab was occurring. After every blood draw 
(every 5-10 min during the first 4 h of testing and every 30 min during the final 2 h of 
testing), the participants rated their subjective well-being.   
 
 
 
 
 
 
Figure 2. Study Design for Specific Aim 1, 2, and 3.  
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Detailed Methods 
Medications: During each trial the participants were instructed not to alter their 
medication use and to continue to take their prescription medication at the same dosage, 
time, and frequency that they have been taking them.  
Diet: During day two and the morning of day three of each experimental trial, the 
participants were provided with a standardized diet. Prior to beginning the study, total 
daily energy expenditure was estimated for each participant. This was accomplished by 
measuring resting energy expenditure (REE) using indirect calorimetry (Parvomedics) 
and free-living physical activity energy expenditure with a BodyMedia® armband 
(BodyMedia, Inc, Pittsburgh, PA). The sum of these two measurements was used as an 
estimate of total daily energy requirements. For all the meals, the percent of energy from 
each macronutrient was 50% carbohydrate, 35% fat, and 15% protein. The breakfast meal 
was 585 Calories and consisted of an English muffin, cheddar cheese, one large egg, 
ham, hash brown, ketchup, and apple or orange juice. The lunch meal was 583 Calories 
and consisted of white bread, ham, mayonnaise, cheddar cheese, a granola bar, and apple 
or orange juice. The dinner meal was spaghetti noodles, spaghetti sauce with beef added, 
garlic bread, a lemon lime flavored soda, and 1.5 g of acetaminophen (to assess gastric 
emptying). The Caloric content of the dinner meal was calculated by subtracting 1,186 
Calories (from breakfast and lunch meals) from the estimated total daily energy 
expenditure for that participant. On the morning of day 3, the participants were given the 
same standardized breakfast that they consumed during day 2.  
Gastric Emptying: During day two, the participants ingested 1.5 g of acetaminophen with 
the dinner meal in the lab. The area under the curve (AUC) provides an estimate of the 
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gastric emptying rate [70]. Prior research has shown that acetaminophen does not alter 
the glycemic response to a test meal in healthy or diabetic individuals [71] and pilot data 
in our lab showed that acetaminophen did not interfere with YSI or CGMS glucose 
measurements (unpublished data).  
Indirect Calorimetry and Heart Rate: A ParvoMedics TrueOne® 2400 metabolic 
measurement system (Sandy Lake, UT) was used to measure REE and energy 
expenditure and whole body substrate oxidation during exercise and throughout each trial 
according to manufacturer specifications. The REE measurement was conducted in the 
morning after an overnight fast. Prior to the REE measurement, the participants sat 
quietly for ~10-15 min prior to the REE measurement. During the REE, participants lied 
supine in a recliner for 30 min while all expired air was collected and analyzed for O2 and 
CO2 content. The O2 and CO2 values were converted to a REE estimate using the 
ParvoMedics software (Weir Equation).   
During testing for each trial, indirect calorimetry was used to measure energy 
expenditure, VO2, and whole body substrate oxidation at three different time points 
including: 1) for a duration of ~45 min prior to dinner (starting ~115 min prior to dinner 
and during exercise during the RE→M trial), 2) for a duration of ~45 min after dinner 
(starting ~45 min after dinner and during exercise during the M→RE trial), and 3) for a 
duration of 15-30 min starting ~3.5 h after dinner. Heart rate was measured during 
exercise only using a Polar heart rate monitor.  
Subjective Perceived Exertion and Well-being: Ratings of perceived exertion (RPE) were 
measured at the end of every RE set using Borg’s 6-20 scale to determine how hard the 
participants perceived each set to be.  Well-being was assessed using a computerized 0-
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100 cm visual analog scale after every blood draw. The question was worded “How 
strong is your overall feeling of well-being (pleasure)” and the participants marked a 
single horizontal line through the vertical line on the scale in-between the anchors “not at 
all” and “extremely”.       
Blood Glucose Monitoring: A CGMS (iPro CGMS; Medtronic, Minneapolis, MN, USA) 
was used to assess free-living glucose responses during the testing period. The CGMS 
was inserted just beneath the skin in the periumbilical region of the abdomen. The 
participants were instructed to take and record a finger stick blood glucose (Accu-Chek 
Compact Plus; Roche Diagnostics, Indianapolis, IN), and to take one finger stick blood 
glucose prior to each meal during the testing period. The fingerstick blood glucose 
readings were used to calibrate the CGMS according to manufacturer specifications. Data 
from the CGMS was processed using Solutions Software for CGMS iPro (Version 2.0A). 
Resistance Exercise: For baseline testing, each participant was familiarized with RE so 
that they were not naïve to RE before testing. First, the participants completed 
familiarization session one to teach them how to properly perform each exercise. During 
familiarization one, the weight for the resistance exercises was light (~10-40% of 
bodyweight) and the participants performed 1-2 sets of 10 repetitions with a 1 min rest 
period between each set of the following exercises (performed in this order): Leg press, 
seated calf raises, seated chest flies, seated back flies, back extensions, shoulder raises, 
leg curls, and abdominal crunches. Next, after familiarization session one, strength 
testing ensued and the 10 repetition maximum (10-RM) for each exercise described 
previously (except abdominal crunches) was determined. During 10-RM testing, each 
exercise began with a warm-up set (~10-40% of bodyweight), and then for each 
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subsequent set additional weight was added until the 10-RM for the exercise was 
determined (~2 min of rest was allotted between each attempt). Lastly, after the strength 
testing session and after at least a 3 d recovery period, the participants performed 
familiarization session two. For familiarization session two, the participants performed 
three sets (1-2 min rest between sets) of 10 repetitions using the 10-RM weight 
determined previously for the exercises described previously. The first set for each 
exercise was a warm-up set and the weight used was 50% of the participants 10-RM. 
After the warm-up set, the weight for the next two sets was the participants previously 
determined 10-RM. After familiarization session one, strength testing, and familiarization 
session two were completed, the participants began performing the exercise trials. During 
the RE→M and M→RE trials, the acute bout of exercise during these trials was the same 
as familiarization session two.   
Blood Collection and Analysis: Upon arrival for testing on day two, a venous catheter 
was inserted into the antecubital vein of the participant. During the first 4 h of testing a 
blood sample was taken every 5 or 10 min, and during the last ~2 h of testing a blood 
sample was taken every 30 min. Blood samples at each time point (~1.5 – 8.5 mL) were 
transferred immediately into chilled EDTA tubes pretreated with Aprotinin (Thermo 
Fisher Scientific, Inc, USA) only (for TAG samples), chilled EDTA tubes pretreated with 
dipeptidyl peptidase-4 inhibitor (Millipore, USA), Pefabloc® SC (DSM Nutritional 
Products AG, Switzerland), and Aprotinin (Millipore, USA, for hormone, glucose, and 
FFA), or EDTA tubes not treated with any protease inhibitors (for acetaminophen assay). 
Within 30 min from collection, the blood was separated by centrifugation at 3,000 RPM 
for 10 min at 4°C and frozen at -80˚ C until analysis. 
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Separation of Lipoprotein Species: Separation of plasma chylomicron (Sf > 400), VLDL-
1 (Sf 60-400), and VLDL-2 (Sf 20-60) was performed using density gradient 
ultracentrifugation, essentially as described by Karpe et al. [72], but with minor 
modification as we used a different rotor. Using fresh plasma, 0.1 g of KBr was mixed 
into 1 mL of plasma to bring the density up to 1.1 g/L in a polyallomer ultracentrifuge 
tube (14 x 89 mm. tube, Beckman Coulter, Inc, USA). Next, 3 ml of KBr salt solution of 
density 1.1 g/l was carefully layered on top of the plasma. Next, 4 ml of NaCl solution of 
density 1.065 g/l was layered on top of the 1.1 g/l solution, followed by 3 ml of KBr 
solution of density 1.020 g/l being layered on top of the 1.065 g/l solution. Lastly, 1 ml of 
NaCl solution of density 1.006 g/l was layered on top of the 1.020 g/l solution. 
Ultracentrifugation was performed using a TH-641 swinging bucket rotor at 40,000 RPM 
and 10° C. For the separation of each lipoprotein species, consecutive ultracentrifucations 
of 32 min (chylomicrons), 3 h and 28 min (VLDL-1), and 16 h (VLDL-2) were 
performed. After each run, the top 1 mL layer was carefully removed and frozen at -80°C 
until analysis. Before the next run, the tube was refilled with 1 mL of NaCl solution of 
density 1.006 g/l. 
Biochemical Analyses: Plasma TAG (Infinity™, Thermo Fisher Scientific Inc, USA), 
free fatty acids (Wako Chemicals USA, Inc. USA), and acetaminophen concentrations 
were determined using a colorimetric assay (Cambridge Life Science LTD, United 
Kingdom). Plasma hormone concentrations were determined from the same sample using 
a MILLIPLEX magnetic bead-based immunoassay (Millipore, USA). Hematocrit was 
measured after every blood draw and all samples were corrected for changes in plasma 
volume. Plasma volume variations (ΔVP) were calculated from hematocrit variations (Ht, 
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Ht1 = baseline Ht, Ht2 = after baseline Ht) using the following formula: % ΔVP = 
100*[(Ht1 – Ht2) / (Ht2*(100-Ht1))]. Corrected plasma values were calculated using the 
following formula: Corrected Value = (Initial Value*100) / (100- ΔVP). 
Beta-cell function: Model based beta-cell function parameters were calculated using a 
mathematical model developed by Mari et al. [73-74] and the insulin secretion rates (ISR) 
used in the model were calculated by deconvoluting c–peptide concentrations [75]. 
Briefly, beta-cell glucose sensitivity is the slope of the dose response relation between 
insulin secretion, glucose concentration, and the potentiation factor. The potentiation 
factor ratio is the ratio between potentiation at the end of the dinner meal (220-240 min) 
and the initial value (0-20 min). Rate sensitivity represents the enhancement of insulin 
secretion proportional to the rate of change of plasma glucose. 
Calculations: For specific aim 1 and 3, postprandial responses were quantified using the 
incremental area under the curve (iAUC), which was calculated using the trapezoidal 
method [76]. Gastric emptying was quantified using the iAUC. For specific aim 2, the 
data from the CGMS included 1) average nocturnal glucose concentration from 12-6 
a.m., 2) time spent hyperglycemic (blood glucose > 180 mg/dL), 3) time spent 
hypoglycemic (blood glucose < 70 mg/dL), 4) the 4 h postprandial glucose iAUC to the 
breakfast meal on day 3 of each protocol, 5) the average morning blood glucose 
concentrations (6 a.m. to 12 p.m.), and 6) 24 h average blood glucose concentrations and 
24 h glycemic variability from the start of lunch on day two thru the beginning of lunch 
on day three of each testing trial. Glycemic variability was assessed using the M-value 
[77], mean amplitude of glycaemic excursion (MAGE) [78], J-index [79], continuous 
overlapping net glycaemic action (CONGA-1, -2, and -4) [80], and the liability index 
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[81]. Insulin clearance was calculated as the molar ratio of insulin to c-peptide at each 
time point, as a percent ((1-[insulin/c-peptide pmol/L])*100). The change in the glucose 
and TAG iAUC was calculated by subtracting the iAUC during the NoRE trial from the 
iAUC during either the M→RE or RE→M trial. 
Statistical Analysis: Statistical analyses were performed using the IBM SPSS statistical 
software version 20 (IBM Corporation, Armonk, NY, USA). For specific aim 1 and 3, a 
repeated measures ANOVA with follow-up Bonferroni adjusted post hoc t-tests were 
used to compare the 4 h post-dinner iAUC responses for all variables. Significance was 
set at P ≤ 0.05. For Specific Aim 2, a repeated measures ANOVA with Bonferroni 
adjusted post hoc t-tests was used to compare 1) average nocturnal glucose concentration 
from 12-6 a.m., 2) time spent hyperglycemic (blood glucose > 180 mg/dL), 3) time spent 
hypoglycemic (blood glucose < 70 mg/dL), 4) the 4 h post-meal glucose iAUC to the 
breakfast meal on day 3 of each protocol, 5) the average glucose concentrations from 6 
a.m. to 12 p.m. on day three of each trial and from the start of lunch on day two thru the 
start of lunch on day three, and 6) all of the glycemic variability indexes listed above. The 
values for the baseline characteristics are reported as means ± standard deviation, while 
all other values are reported as means ± standard error of the mean. 
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CHAPTER 3 - RESULTS 
 
Participant Characteristics 
 
 
The participant characteristics are listed in Table 3. A total of 13 obese (BMI 30-
45 kg/m2) men and women (5 males) with type 2 diabetes completed this study. The 
participants were weight stable while enrolled in this study as body weight was not 
significantly different (P > 0.05) between study days (NoRE body weight: 104.2 ± 22.8 
kg; RE→M body weight: 103.9 ± 22.7 kg; M→RE body weight: 104.2 ± 22.9 kg).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Participant Characteristics (N = 13, 5 Males) 
Age (yr)   48.5 ± 11.9 
Height (m)   1.67 ± 0.11 
Weight (kg) 103.2 ± 22.8  
Body mass index (kg/m2)   36.7 ± 5.3 
Body fat percent   39.5 ± 8.6 
Fasting Glucose (mg/dL)     148 ± 41 
Fasting Hemoglobin A1c (% [mmol/mol])     7.2 ± 1.1 [55] 
Diagnosed with Type 2 Diabetes (yr)      3.7 ± 3.9  
Participants using diabetes medication, n          12 
Values are means ± standard deviation  
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Indirect Calorimetry, Heart Rate, and Rating of Perceived Exertion During 
Exercise     
 
 The metabolic data and average rating of perceived exertion during each RE 
session are listed in Table 4. The average heart rate was 4 beats per minute higher (P < 
0.05) during the M→RE trial (110 ± 4 bpm) compared to the RE→M trial (106 ± 4 bpm), 
while all other variables were similar between RE trials (P > 0.05). In addition, RE 
significantly increased oxygen consumption, energy expenditure, and the respiratory 
exchange ratio compared to NoRE (P < 0.05). 
 
Table 4. Metabolic data and rating of perceived exertion during 
resistance exercise session.  
 RE→M NoRE-1 
Time (min)      46 ± 1       46 ± 1 
Oxygen consumption (ml kg-1 min-1)     6.1 ± 0.4      2.9 ± 0.1* 
Energy Expenditure (Gross Calories)    140 ± 14      63 ± 3*  
Respiratory Exchange Ratio   1.00 ± 0.01   0.83 ± 0.01* 
Heart Rate (bpm)    106 ± 4  
Average RPE (BORG 6-20 scale)      12 ± 1   
 M→RE NoRE-2 
Time (min)    47 ± 1     47 ± 1 
Oxygen consumption (ml kg-1 min-1)   6.0 ± 0.3    2.9 ± 0.1* 
Energy Expenditure (Gross Calories)  141 ± 14       66 ± 5*  
Respiratory Exchange Ratio 1.00 ± 0.01  0.87 ± 0.01*† 
Heart Rate (bpm)  110 ± 4**  
Average RPE (BORG 6-20 scale)    12 ± 1  
Values are means ± standard error of the mean.   
The data under NoRE-1 is during the same time frame (i.e. before 
dinner) as RE→M but during the NoRE trial, while the data under 
NoRE-2 is during the same time frame (i.e. after dinner) as M→RE 
but during the NoRE trial.    
*P < 0.05 compared to RE→M or M→RE. 
**P < 0.05 compared to heart rate during the RE→M trial.   
†P < 0.05 compared to NoRE-1. 
For the variables time, oxygen consumption, energy expenditure, 
respiratory exchange ratio, and heart rate, only data for N = 12 is 
reported. For RPE, data for N = 13 is reported.  
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Blood Glucose Concentrations During Mixed Meal Testing  
 
 The blood glucose time course (Figure 3A), pre-dinner iAUC (Figure 3B), and 
post-dinner iAUC (Figure 3C) are illustrated in Figure 3. Performing RE prior to dinner 
reduced blood glucose concentrations, as the 1.6 h blood glucose iAUC was significantly 
lower (P < 0.05) during the RE→M trial compared to the NoRE and M→RE trials. The 
postprandial blood glucose iAUC was reduced by 33% and 18% during the M→RE trial 
and RE→M trial, respectively, compared to the NoRE trial (both P < 0.05). The 4 h 
blood glucose iAUC was not different between exercise trials (P > 0.05).  
 
Figure 3. Blood Glucose Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.  
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Individual Glucose Responses 
 
Figure 4 illustrates the change in the 4 h glucose iAUC during each RE trial for 
each individual person that participated in this study. Interestingly, 6 / 13 people had 
better improvements in glycemic control with post-meal RE, while 6 / 13 people had 
better improvements with pre-meal RE, and one person did not see an improvement with 
RE at either time. Thus, overall it appears that neither RE time is better compared to the 
other at lowering post-meal glucose concentrations. In three cases, it appears that RE 
timing played a role in exercise insensitivity. For example, subject 6 had a worsening of 
glycemic control with pre-meal RE, but post-meal RE improved glycemic control in this 
individual. Subject 10 and 11 had a worsening of glycemic control with post-meal RE, 
but pre-meal RE improved glycemic control in these individuals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Change in glucose iAUC during each exercise trial in each subject. 
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Triacylglycerol Concentrations During Mixed Meal Testing  
 
The total TAG, chylomicron TAG, VLDL-1 TAG, and VLDL-2 TAG time course 
and iAUC during each trial are illustrated in Figure 5A and 5B, 6A and 6B, 7A and 7B, 
and 8A and 8B, respectfully. During the M→RE trial, the postprandial total TAG iAUC 
and VLDL-1 TAG iAUC was reduced by ~92% compared to the NoRE and RE→M 
trials (P < 0.05). The chylomicron TAG iAUC and VLDL-2 TAG iAUC was not 
different between trials (P > 0.05).    
 
 
 
 
 
 
 
 
 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Total Triacylglycerol Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Figure 6. Chylomicron Triacylglycerol Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Figure 7. VLDL-1 Triacylglycerol Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Figure 8. VLDL-2 Triacylglycerol Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Individual Triacylglycerol Responses 
 
Figure 9 illustrates the individual TAG responses during each RE trial in each 
subject. In 7 / 13 people, post-meal RE was better at lowering postprandial TAG 
concentrations compared to pre-meal RE, while pre-meal RE was better (only slightly) in 
3 / 13 people compared to post-meal RE. In three individuals, neither pre-meal nor post-
meal RE improved postprandial TAG concentrations.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Change In Triacylglycerol iAUC During Each Exercise Trial In Each Subject. 
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Free Fatty Acid Concentrations During Mixed Meal Testing 
 
The plasma FFA time course (Figure 10A), pre-dinner FFA iAUC (Figure 10B), 
and post-dinner FFA iAUC (Figure 10C) during testing are illustrated in Figure 10. The 
rise in pre-meal FFA concentrations was significantly attenuated (lower pre-meal 1.6 h 
FFA iAUC) during the RE→M trial compared to the NoRE and M→RE trials (P < 0.05). 
Similarly, the drop in postprandial FFA concentrations was significantly less (higher [less 
negative] post-meal FFA iAUC) during the RE→M trial compared to the NoRE and 
M→RE trials (P < 0.05).  
 
Figure 10. Free Fatty Acid Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Insulin Concentrations During Mixed Meal Testing 
 
The insulin time course (Figure 11A), pre-dinner iAUC (Figure 11B), and post-
dinner iAUC (Figure 11C) are illustrated in Figure 11. The pre-dinner 1.6 h insulin 
iAUC was not different between trials (P > 0.05). The postprandial 4 h insulin iAUC was 
39% and 31% lower during the M→RE and RE→M trials, respectively, compared to the 
NoRE trial (P < 0.05).   
Figure 11. Insulin Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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 C-peptide Concentrations During Mixed Meal Testing 
 
The c-peptide time course (Figure 12A), pre-dinner iAUC (Figure 12B), and 
post-dinner iAUC (Figure 12C) are illustrated in Figure 12. The pre-dinner 1.6 h c-
peptide iAUC was significantly lower during the RE→M trial compared to the M→RE 
and NoRE trials (P < 0.05), indicating RE decreased c-peptide concentrations prior to 
dinner. The postprandial 4 h c-peptide iAUC was 45% lower during the M→RE trial 
compared to the NoRE trial (P < 0.05). Despite the postprandial 4 h c-peptide iAUC 
being 35% lower during the M→RE trial compared to the RE→M, this difference was 
not significant (P > 0.05).    
Figure 12. C-peptide Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Insulin Kinetics During Mixed Meal Testing 
 
The insulin secretion time course (Figure 13A) and iAUC (Figure 13B) are 
illustrated in Figure 13. The postprandial 4 h ISR iAUC was 40% lower during the 
M→RE trial compared to the NoRE trial (P < 0.05). There were no other significant 
differences in insulin secretion between trials (P > 0.05).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Insulin Secretion Rates During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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The insulin clearance time course (Figure 14A) and iAUC (Figure 14B) are 
illustrated in Figure 14. The postprandial 4 h insulin clearance iAUC was significantly 
different between each trial (P < 0.05) and was highest in the RE→M trial, lowest in the 
NoRE trial, while insulin clearance during the M→RE trial was in between the other two 
trials. 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Insulin Clearance During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Glucagon Concentrations During Mixed Meal Testing 
 
The glucagon time course (Figure 15A), pre-dinner iAUC (Figure 15B), and 
post-dinner iAUC (Figure 15C) during mixed meal testing are illustrated in Figure 15. 
Pre-meal glucagon responses were not different between trials (P > 0.05). The 
postprandial 4 h glucagon iAUC was significantly lower (P < 0.05) during the RE→M 
trial compared to the other trials because glucagon increased slightly during this trial 
prior to the meal, and thus when the meal was eaten glucagon concentrations dropped 
further compared to the other trials.   
 
Figure 15. Glucagon Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Incretin Hormone Concentrations During Mixed Meal Testing 
 
The GIP time course (Figure 16A), pre-dinner iAUC (Figure 16B), and post-
dinner iAUC (Figure 16C) during mixed meal testing are illustrated in Figure 16. 
Neither pre- nor post-dinner GIP concentrations were significantly different between the 
different trials (P > 0.05).   
 
Figure 16. GIP Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
 
 
 
 
RE-M M-RE NoRE
-10000
-8000
-6000
-4000
-2000
0
B. Pre-meal GIP iAUC
G
IP
 (p
g/
m
L 
pe
r 
1.
6 
h)
RE-M M-RE NoRE
0
50000
100000
150000
C. Post-meal GIP iAUC
G
IP
 (p
g/
m
L 
pe
r 
4 
h)
-90 -60 -30 0 30 60 90 120150180210240
0
200
400
600
800
RE-M
M-RE
NoRE
A. GIP Time Course
RE-M M-RE
Meal
Time (min)
G
IP
 (p
g/
m
L)
42	
	
RE-M M-RE NoRE
-5000
-4000
-3000
-2000
-1000
0
B. Pre-meal GLP-1 iAUC
G
LP
-1
 (p
g/
m
L 
pe
r 
1.
6 
h)
-90 -60 -30 0 30 60 90 120150180210240
50
100
150
200
250
RE-M
M-RE
NoRE
A. GLP-1 Time Course
RE-M M-RE
Meal
Time (min)
G
LP
-1
 (p
g/
m
L)
RE-M M-RE NoRE
5000
10000
15000
C. Post-meal GLP-1 iAUC
P < 0.05
P < 0.05
G
LP
-1
 (p
g/
m
L 
pe
r 
4 
h)
The GLP-1 time course (Figure 17A), pre-dinner iAUC (Figure 17B), and post-
dinner iAUC (Figure 17C) during testing are illustrated in Figure 17. Pre-dinner GLP-1 
concentrations were not different between trials (P > 0.05). However, during the M→RE 
trial, the postprandial 4 h GLP-1 iAUC was 50% and 49% lower compared to the RE→M 
and NoRE trial, respectfully (P < 0.05), indicating post-dinner RE reduced postprandial 
GLP-1 concentrations.    
Figure 17. GLP-1 Concentrations During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Acetaminophen (Gastric Emptying) Responses 
 
The acetaminophen time course (Figure 18A) and post-dinner iAUC (Figure 
18B) are illustrated in Figure 18. The 4 h acetaminophen iAUC, 2 h acetaminophen 
iAUC, the change in acetaminophen concentrations from 40-90 min post-meal (which 
corresponds to the time frame when RE was performed), or the time to peak 
concentration was not significantly different between trials (P > 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Acetaminophen Concentrations (Gastric Emptying) During Mixed Meal 
Testing. 
Values are means ± standard error of the mean.   
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Energy Expenditure and Whole Body Substrate Oxidation 
 
Table 5 lists the average energy expenditure and respiratory exchange ratio 
(RER) from ~min 210 – 240 after dinner. There were no significant differences in energy 
expenditure or RER between the trials.    
 
Table 5. Energy Expenditure and Substrate Oxidation ~3.5 - 4 h After Dinner Meal 
 Energy Expenditure (kcal/min) RER 
NoRE 1.4 ± 0.1 0.85 ± 0.01 
RE→M 1.4 ± 0.1 0.83 ± 0.01 
M→RE 1.5 ± 0.1 0.83 ± 0.01 
Values are means ± standard error of the mean.  
RER = Respiratory exchange ratio (lower number = greater fat oxidation, higher number 
= greater carbohydrate oxidation).  
 
 
Beta-cell Function Responses 
 
 Table 6 lists the beta-cell function parameters during each testing trial. There 
were no significant differences (P > 0.05) in beta-cell glucose sensitivity, rate sensitivity, 
or the potentiation factor ratio between trials.  
 
Table 6. Beta-cell Function Parameters 
 NoRE RE→M M→RE 
Beta-cell Glucose Sensitivity 
((pmol/(min.m2.mM)) 39 ± 5 50 ± 8 50 ± 9 
Rate Sensitivity  
(pmol/(m2.mM)) 306 ± 93 402 ± 141 307 ± 86 
Potentiation Factor Ratio  
(fold) 1.25 ± 0.18 0.87 ± 0.08 1.01 ± 0.13 
Values are means ± standard error of the mean.  
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Subjective Well-being and Exercise Timing Preference  
 
The pre-dinner subjective well-being time course (Figure 19A), pre-dinner iAUC 
(Figure 19B), post-dinner time course (Figure 19C), and post-dinner iAUC (Figure 
19D) are illustrated in Figure 19. The change in subjective well-being, rather than the 
absolute well-being value, was used because the initial (baseline) subjective well-being 
value was significantly different between trials (P < 0.05), thus to better capture the 
change in well-being, change scores were used. Prior to the meal during the RE→M trial, 
the 1.6 h subjective well-being iAUC was significantly greater compared to the NoRE 
trial (P < 0.05) and tended to be greater compared to the M→RE trial (P = 0.064), 
indicating that subjective well-being increased more when the participants exercised prior 
to the meal compared to when they did not exercise. After the meal, the 4 h subjective 
well-being iAUC was significantly greater (P < 0.05) during the RE→M and M→RE 
trials, compared to the NoRE trial, and there was no statistically significant difference 
between exercise trials.      
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Figure 19. Subjective Well-being During Mixed Meal Testing. 
Values are means ± standard error of the mean.   
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Nocturnal Glucose Responses and Post-breakfast Glucose Responses  
 Nocturnal and post-breakfast GGMS measured glucose responses for each trial 
are illustrated in Figure 20 and 21 and listed in Table 7. There were no significant 
differences (P > 0.05) between trials for average nocturnal blood glucose concentrations, 
nocturnal time spent hyperglycemic or hypoglycemic, the 4 h post-breakfast glucose 
iAUC responses, or the post-breakfast time spent hyperglycemic and hypoglycemic.     
 
Figure 20. Nocturnal Blood Glucose Concentrations After Testing In The Lab 
Values are means. 
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Figure 21. Postprandial Glucose Concentrations After Breakfast. 
Values are means.  
 
Table 7. Nocturnal and Post-Breakfast Glucose Responses 
  NoRE RE→M M→RE 
Nocturnal Glucose Responses (12-6 a.m.)   
  Average Blood Glucose (mg/dL) 114 ± 9 107 ± 7 115 ± 10 
  Time Hyperglycemic (min) 
  (Blood Glucose > 180 mg/dL)     0.4 ± 0.6     2.7 ± 3.9   14.6 ± 10.6 
  Time Hypoglycemic (min) 
  (Blood Glucose < 70 mg/dL)     26.5 ± 30.5   17.7 ± 7.8   6.9 ± 3.7 
Post-Breakfast Glucose Responses    
  Average Blood Glucose (mg/dL)    160 ± 11    157 ± 12 163 ± 17 
  4 h iAUC (mg/dL per 4 h)    1288 ± 307    1486 ± 419 1356 ± 387 
  Time Hyperglycemic (min) 
  (Blood Glucose > 180 mg/dL)      80.8 ± 22.7     43.3 ± 19.0   66.3 ± 27.5 
  Time Hypoglycemic (min) 
  (Blood Glucose < 70 mg/dL) 0 0 0 
Values are means ± standard error of the mean.  
The data for the nocturnal glucose response is for N = 13. Due to a malfunction in one of 
the CGMS during testing, data for one subject was lost thus data for post-breakfast 
glucose responses is for N = 12.  
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Figure 22 illustrates the 24 h blood glucose concentrations from the beginning of 
lunch on day two of each trial to the beginning of lunch on day three of each trial. Table 
8 lists the average blood glucose concentrations and glycemic variability over 24 h 
between the start of breakfast on day two of each trial thru the start of breakfast on day 
three of each trial. There were no significant differences (P > 0.05) for any variable 
measured.  
Figure 22. Blood Glucose Concentrations Over 24 Hour Period. 
Values are means.  
Data is for N = 11 participants as 2 participants had missing data so they were excluded. 
 
 
 
 
 
50	
	
Table 8. Average Blood Glucose and Glycemic Variability Over 24 h  
 NoRE RE-M M-RE 
Average Blood Glucose (mg/dL)          141 ± 8          130 ± 7        140 ± 10 
Standard Deviation         33.4 ± 3.5         31.1 ± 4.3        38 ± 4.4 
CONGA-1          124 ± 7          115 ± 6      123 ± 9 
CONGA-2          112 ± 7          105 ± 6      110 ± 8 
CONGA-4          105 ± 7          101 ± 6      100 ± 8 
Liability Index          973 ± 181          887 ± 245    1163 ± 241 
J-Index     10,125 ± 1,143       8,760 ± 1,309 10,931 ± 1,799 
MAGE            85 ± 10            82 ± 12        86 ± 12 
M-Value       2,286 ± 121       2,116 ± 111   2,263 ± 159 
Values are means ± standard error of the mean.  
Data is for N = 11 participants as 2 participants had missing data so they were excluded. 
 
 
Fasting Measures The Morning Following the Acute Resistance Exercise Session 
Fasting blood glucose, insulin, c-peptide, hepatic insulin clearance, hepatic insulin 
resistance (HOMA-IR), whole body insulin sensitivity (QUICKI), and TAG measures are 
listed in Table 9. There were no significant differences between trials in any parameter 
measured (P > 0.05).   
 
 
 
 
Table 9. Morning Fasting Measures The Day After Testing In The Lab   
 NoRE RE→M M→RE 
Blood Glucose (mg/dL) 121 ± 7 120 ± 6       120 ± 10 
Insulin (pmol/l)        290 ± 43        256 ± 37       301 ± 53 
C-Peptide (pmol/l)      1537 ± 181      1378 ± 113     1465 ± 194 
Insulin Clearance (%)          81 ± 2           82 ± 2         80 ± 2 
HOMA-IR      12.58 ± 1.98      10.98 ± 1.77    12.05 ± 1.92 
QUICKI       0.28 ± 0.01        0.28 ± 0.01      0.28 ± 0.05 
Triacylglycerol (mg/dL)        134 ± 14        133 ± 14       138 ± 16 
Values are means ± standard error of the mean. 
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CHAPTER 4 - DISCUSSION 
Main Findings 
 
Knowledge of the best time to perform RE around dinner will provide health care 
professionals with a better idea of how to personalize RE prescription to optimize its 
metabolic health benefits in obese patients with T2D. Thus, the overarching goal of this 
project was to identify the best time, either before or after dinner, to perform RE to lower 
postprandial glucose and TAG concentrations, two important cardiovascular disease risk 
factors in obese patients with T2D. The key findings of this study are: 1) Both pre- and 
post-dinner RE reduces postprandial glucose concentrations, while only post-dinner RE 
reduces both postprandial glucose and TAG concentrations, 2) Both pre- and post-dinner 
RE reduces insulin concentrations,  but via different mechanisms as pre-dinner RE 
enhances insulin clearance, whereas post-dinner RE reduces pancreatic insulin secretion 
and enhances insulin clearance, 3) Post-dinner RE reduces postprandial GLP-1 
concentrations while pre-dinner RE does not, 4) Pre-dinner RE reduces pre-dinner FFA 
concentrations, 5) Gastric emptying, beta-cell function, post-dinner substrate oxidation, 
post-dinner GIP concentrations, and nocturnal and postprandial glucose concentrations or 
insulin sensitivity the following morning are not altered by acute RE, and 6) RE 
improved well-being when performed before or after dinner. Taken together, post-dinner 
RE improves metabolic control better than pre-dinner RE in obese patients with T2D, and 
these benefits are short lived and do not last into the overnight period or into the next day. 
Importantly, RE improved well-being, making it a feasible option for obese patients with 
T2D. 
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Glucose Responses 
Previous research has shown that in patients with T2D an acute bout of RE prior 
to a meal (s) lowers postprandial glucose concentrations [49] or improves 24 h glycemic 
control [50] within 24 h of the RE session, although one study showed acute RE had no 
impact on postprandial glucose concentrations [38]. In line with some of this previous 
work, in the current study the acute RE session prior to the dinner meal lowered 
postprandial glucose concentrations. Further, the current study is the first to examine how 
post-meal RE impacts postprandial blood glucose concentrations, and similar to pre-
dinner RE, post-dinner RE produced a decrease in the postprandial blood glucose iAUC. 
Thus, it appears that neither RE time is better compared to the other as far as lowering 
postprandial blood glucose concentrations.  
There was tremendous inter-individual variation in the effect of RE on 
postprandial glucose concentrations in the current study with some individuals have an 
adverse response (i.e. increase in glucose iAUC with RE), and this has been reported by 
other researchers as well with aerobic exercise [36]. Bouchard et al. [82] have reported 
that ~7% of people that exercise experience adverse responses in cardiovascular and 
diabetes risk factors. Further, Bouchard et al. [82]concluded that identifying the 
predictors of such unwarranted responses and how to prevent them will aid in better, 
more personalized exercise prescriptions. Interestingly, in the current study one 
participant had a worsening of glycemic control with pre-meal RE (adverse response), 
but post-meal RE improved glycemic control in this individual. In addition, two 
participants had a worsening of glycemic control with post-meal RE, but pre-meal RE 
improved glycemic control in these individuals. Taken together, these data suggest that 
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the ability to improve glycemic control with acute RE may be dependent on the timing of 
the RE session relative to a meal in some cases. In other words, manipulating RE timing 
may make most people exercise responders. This data has important implications for 
personalized medicine, and will help make more effective exercise prescriptions that will 
maximize the metabolic benefits of RE in obese patients with T2D.     
The postprandial glucose time course during each RE trial was drastically 
different. During the first 45 min after the meal, the rise in blood glucose concentrations 
was similar between trials. During the pre-meal RE trial, postprandial glucose 
concentrations were lower in the middle of the postprandial period (from ~1-3 h) 
compared to the NoRE trial. However, during the post-meal RE trial glucose 
concentrations were lower predominantly during exercise (from ~45 min – 1.5 h post-
meal), and rebounded at the cessation of exercise to NoRE trial levels. These 
observations suggest that different glucose lowering mechanisms may be at play 
depending on the timing of RE. The rate of gastric emptying plays a large role in the 
postprandial glucose response, but in the current study gastric emptying was unaltered 
with RE, which suggests changes in gastric emptying are not responsible for reductions in 
blood glucose concentrations with RE.  Instead, it is likely that during the pre-dinner RE 
trial, insulin sensitivity was increased prior to the meal which improved insulin action (an 
effect that may have been partially mediated by reduced pre-meal free fatty acid 
concentrations) in the previously exercised skeletal muscle and possibly the liver prior to 
ingestion of the dinner meal. This effect would increase glucose uptake into skeletal 
muscle and reduce hepatic glucose output to a greater extent compared to not exercising. 
This hypothesis is supported by the reduced insulin concentrations (thus improved insulin 
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sensitivity) observed in this study. In addition, pre-meal RE probably increased 
postprandial skeletal muscle and liver blood flow (which is related to enhanced insulin 
sensitivity), which increased capillary recruitment and blood flow through previously 
non-flowing capillaries, thus allowing more widespread glucose uptake via the GLUT-4 
transporter. This idea is supported by the work of Philips et al. [83], who showed that 
prior RE enhanced postprandial leg blood flow responses, compared to no exercise. 
During the post-meal RE trial, it is likely that the elevated insulin concentrations due to 
the prior meal on top of the skeletal muscle contractions worked synergistically to 
increase skeletal muscle blood glucose uptake, and that this mechanism at least partially 
contributed to reducing postprandial blood glucose concentrations during this trial. This 
potential mechanism is supported by the work of Larsen et al. [53] in which moderate 
intensity cycling exercise, beginning 45 min after breakfast, dramatically increased the 
rate of disappearance of labeled glucose. Once the post-dinner RE session was over, 
blood glucose concentrations rebounded to NoRE concentrations, and it is not clear why 
this occurred. It is possible that hepatic glucose output increased during RE and remained 
elevated immediately after exercise for a short time while glucose uptake into skeletal 
muscle was reduced because of the cessation of muscle contractions and the lower insulin 
concentrations. In support of this, Larsen et al. [53] showed a similar trend such that 
moderate intensity cycling exercise, beginning 45 min after breakfast, also resulted in a 
rebound glycemia effect once exercise stopped that was associated with a slight increase 
in the rate of appearance of 3-[3H] glucose and a slight decrease in the rate of 
disappearance of 3-[3H] glucose immediately after the cessation of post-meal exercise.    
 
55	
	
Triacylglycerol Responses 
For the first time, this study assessed how RE impacts post-meal total TAG 
concentrations in obese patients with T2D. The data suggests that post-meal RE is better 
compared to pre-meal RE at lowering postprandial total TAG concentrations. Although 
no study has directly compared pre-meal exercise to post-meal exercise on the 
postprandial total TAG response in patients with T2D, the available data with AE is in 
line with this finding. For example, in two studies [37, 40] the AE session was performed 
the day prior to the test meal given and in these studies there was no change in 
postprandial total TAG concentrations with AE, compared to a no exercise trial. 
Interestingly, in another study the AE bout was performed starting 90 min after a high fat 
breakfast meal, and in this study the exercise bout significantly reduced the average 
postprandial total TAG response compared to no exercise [48].  
Clearly, the data suggest that exercise timing is of critical importance and that 
post-meal RE is better compared to pre-meal RE at lowering postprandial total TAG 
concentrations in most patients with T2D. Although some individuals had benefits in 
postprandial TAG with both RE times, in 7 / 13 people post-meal RE was better at 
lowering postprandial TAG concentrations compared to pre-meal RE, while pre-meal RE 
was better (and only slightly) in 3 / 13 people compared to post-meal RE. Interestingly, in 
three individuals, neither pre-meal nor post-meal RE improved postprandial TAG 
concentrations and instead these individuals had greater postprandial TAG concentrations 
with RE.   
The majority of TAG in circulation originates from either exogenous sources and 
is in the form of chylomicron particles or endogenous sources from the liver and is in the 
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form of VLDL-TAG [84]. In the current study, both particles were measured to gain an 
understanding of which source of TAG RE modifies. Neither pre-meal nor post-meal RE 
modified postprandial chylomicron or VLDL-2 TAG particles. Instead, the reduction in 
postprandial total TAG concentrations with post-dinner RE was primarily mediated by 
reduced VLDL-1 TAG concentrations. The mechanism(s) for the reduction in VLDL-1 
TAG with RE was likely mediated by enhanced hydrolysis of TAG by lipoprotein lipase 
in skeletal muscle and/or by reduced VLDL-1 TAG secretion by the liver.       
Insulin Secretion and Clearance 
In the current study, both pre-dinner RE and post-dinner RE reduced postprandial 
insulin concentrations, and this finding is in line with other work demonstrating acute RE 
~18 h prior to a meal reduces postprandial insulin concentrations (thus improves insulin 
sensitivity) in individuals with T2D [38]. The amount of insulin in circulation is 
dependent on the amount of insulin secreted from the β-cells of the pancreas in addition 
to the amount of insulin cleared from the circulation (which can occur in any organ or 
tissue with an insulin receptor). With pre-dinner RE, the reduction in postprandial insulin 
concentrations was mediated primarily by enhanced insulin clearance, and this finding is 
similar to previous work [38]. During the post-dinner RE trial, we show for the first time 
that the reduction in insulin concentrations was mediated by both increased insulin 
clearance and reduced insulin secretion, although the increase in insulin clearance was 
not as great as compared to the pre-dinner RE trial.  
Pancreatic β-cell insulin secretion is modulated primarily by blood glucose 
concentrations, thus reduced blood glucose concentrations likely mediated the reduction 
in insulin secretion with post-dinner RE. The mechanism by which RE increases insulin 
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clearance is not understood, but one potential explanation may be increased skeletal 
muscle and/or liver blood flow. Increased blood flow in these tissues may increase blood 
flow through previously non-flowing capillaries, allowing more insulin to be exposed to 
and bind to the insulin receptor, internalized, and degraded. This hypothesis is supported 
by the work of Philips et al. [83] who showed that prior RE enhanced postprandial leg 
blood flow responses, compared to no exercise. Another possibility may by that RE 
reduced portal vein glucose and/or FFA concentrations. Given that glucose and FFA have 
been shown to independently and synergistically impair insulin binding to receptors, it is 
possible that a RE induced reduction in these substrates in the portal vein allowed more 
hepatic insulin clearance [85]. However, these mechanisms are only speculative and 
warrant further investigation.                  
Incretin Hormone Responses 
The incretin hormones GIP and GLP-1 are primarily secreted from the small 
intestine in response to nutrient ingestion and help regulate postprandial glucose and 
TAG concentrations via different mechanisms. The current study is the first to examine 
how RE timing impacts postprandial incretin hormone concentrations in obese patients 
with T2D. The data suggest that RE, independent of its timing, does not alter GIP 
concentrations, thus it is likely that GIP did not play a role in the reduction of insulin or 
TAG concentrations with RE. Similarly, in another study after 28 days of metformin or 
placebo treatment, AE  performed prior to a lunch meal did not alter postprandial GIP 
responses in patients with T2D [86].  
In the current study, pre-dinner RE had no effect on postprandial GLP-1 
concentrations. This finding is in line with  previous research, where AE performed prior 
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to a lunch meal did not alter postprandial GLP-1 responses in patients with T2D [86]. On 
the contrary, in the current study post-dinner RE significantly attenuated postprandial 
GLP-1 concentrations, and this effect may have in part contributed to reduced insulin 
secretion (along with reduced glucose concentrations). Interestingly, post-meal AE has 
been shown to accentuate the rise in postprandial GLP-1 concentrations in healthy 
patients [62], whereas in the current study post-dinner RE reduced postprandial GLP-1 
concentrations. The discrepancy in findings between studies is not clear, but may be due 
to different study designs, mode of exercise, different hormonal milieu induced by RE, 
and different populations used.   
Beta-cell Function 
The function of a beta-cell is to release biologically active insulin into the blood 
in response to glucose concentrations. Typically beta-cell function is assessed by the 
sensitivity of the beta-cell to glucose, or the insulin secretion rate at a given blood 
glucose concentration. The effect of RE on beta-cell function is mixed. One study 
demonstrated resistance training improved beta-cell function in individuals without T2D  
[87]. On the contrary, resistance training did not alter beta-cell function in overweight 
Latino adolescent males without T2D [88] or in patients with T2D [89]. In the current 
study, neither beta-cell glucose sensitivity, rate sensitivity, nor insulin potentiation were 
altered with pre- or post-dinner RE in the current study. Although insulin secretion was 
reduced with post-dinner RE in the current study, this was not due to reduced beta-cell 
function but rather reduced glucose concentrations.   
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Subjective Well-being 
One secondary goal of this study was to determine how the different RE times 
altered subjective well-being (pleasure) to determine how feasible each RE time is (i.e. 
did the participants actually enjoy exercising before or after they ate compared to not 
exercising). Importantly, the data suggest that patients with T2D feel better after a meal 
when RE is performed either before or after the meal, and that post-dinner RE does not 
deteriorate subjective-well-being, making it a feasible option. Interestingly, when the 
participants were asked “Did you like exercising before or after dinner better?”, 11 out of 
13 participants preferred RE before dinner. Thus, although post-dinner RE is feasible and 
does not deteriorate subjective well-being, many patients may not be motivated to 
exercise at this time. 
Nocturnal and Post-breakfast Glucose Responses and Insulin Sensitivity the Next 
Day 
Previous research has shown that acute RE either in the morning prior to lunch or 
prior to dinner does not alter average nocturnal blood glucose concentrations [39, 50] and 
our findings are in agreement with these studies. In addition, our study shows that 
changing the RE timing to after dinner and closer to the nocturnal period does not 
modulate nocturnal blood glucose concentrations when measured by CGMS. On the 
contrary, van Dijk et al. [50] reported that an acute bout of RE reduced the average time 
spent hyperglycemic (blood glucose > 180 mg/dL) during the overnight period and 
reduced average morning (6 a.m. - 12 p.m.) glucose concentrations and time spent 
hyperglycemic, whereas we did not observe such a finding. A potential reason for the 
discrepancy in findings between studies could be due to differences in populations and 
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their glycemic control. The subjects in the van Dijk et al. [50] study had an average 
baseline fasting blood glucose of ~177 mg/dL, an average HbA1c of 7.5%, and during 
the no exercise trial had an average nocturnal blood glucose concentrations that was ~160 
mg/dL, were hyperglycemic overnight for an average of ~ 1 h and 42 min, and had an 
average morning period (6 a.m. - 12 p.m.) glucose concentrations of ~155 mg/dL, 
whereas the subjects in our study had an average baseline fasting blood glucose of ~148 
mg/dL, HbA1c of 7.2%, and during the no exercise trial had an average nocturnal blood 
glucose concentration of ~119 mg/dL and spent on average ≤ 16 min hyperglycemic, and 
had an average morning period (6 a.m. - 12 p.m.) glucose concentrations of ~151 mg/dL. 
Therefore, the participants in our study were better controlled diabetics compared to the 
participants in the van Dijk et al. [50] study, thus it is possible the patients in our study 
had less room for improvement.  
In the current study neither pre- nor post-dinner RE altered subsequent 
postprandial glucose responses to a mixed composition breakfast meal the following 
morning (~12-15 h later). This finding is similar to an earlier study that reported RE 
performed ~18 h prior to an oral glucose tolerance test does not improve postprandial 
glucose responses [38] but is not in agreement with another study that showed acute RE 
within 24 h of an oral glucose tolerance test reduced postprandial glucose concentrations 
[49]. One potential reason for the lack of change in glycemic control in the current study 
could be related to the lack of change in insulin sensitivity the following morning. In the 
current study, whole body RE did not increase or decrease fasting blood glucose or 
insulin concentrations or whole body insulin sensitivity (QUICKI) or hepatic insulin 
resistance (HOMA-IR) ~12-15 h later. Likewise, Gordon et al. [68] reported that an acute 
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session of lower body RE did not modulate whole body insulin sensitivity (HOMA2) 24, 
48, or 72 h later in type 2 diabetic patients. In addition, in the current study basal hepatic 
insulin clearance was not different between trials. On the contrary, using an oral glucose 
tolerance test others have found that prior RE within 24 h has reduced postprandial 
insulin concentrations, suggesting improved insulin sensitivity [38, 49].  
Independent of timing, whole body RE did not alter average 24 h blood glucose 
concentrations or glycemic variability in this study, and this finding is in agreement with 
some [39] but not all research [50]. The lack of change in 24 h glycemic variability could 
be attributed to the fact that the whole body RE session in the current study was relatively 
low in energy expenditure (average of ~75-77 Calories above resting energy expenditure) 
and did not improve insulin sensitivity the next day. It may be that a greater energy 
deficit is needed to improve average 24 h blood glucose concentrations and glycemic 
variability in this population.  
Conclusion 
In conclusion, acute post-dinner RE improves postprandial glucose and TAG 
concentrations better than pre-dinner RE in obese patients with T2D. Future studies are 
needed to determine if long-term post-meal exercise training in patients with T2D would 
better improve metabolic health and reduce cardiovascular disease more so than pre-meal 
exercise. 
Limitations 
This project has several limitations including:  
1. Acetaminophen was used to indirectly measure gastric emptying instead of the 
“gold standard” scintigraphy method. However, when validated with scintigraphy, 
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acetaminophen has been shown to yield similar results about gastric emptying 
[90]. 
2. Tracers were not used to determine if post-meal RE reduces exogenous or 
endogenous glucose or TAG rate of appearance and/or increases its rate of 
disappearance.  
3. Numerous hormones may be altered with RE, but we only measured hormones 
that are most critical in glycemic and lipemic control and gastric emptying. 
4. The responses to an acute RE session are being assessed prior to adaptive changes 
that may take place after weeks of RE.  
5. Insulin secretin or clearance was not directly measured using arteriovenous 
differences. 
6. The beta-cell function model used in this study was developed using Caucasian 
participants and has never been validated using other populations. The present 
study included a mix of Caucasian, African American, and Hispanic patients.      
Future Directions 
This is the first study to examine how the timing of RE relative to a meal alters 
glycemic and lipemic control in patients with T2D. This study can serve as a stepping 
stone to several potential future studies with the goal of delineating the best time to 
perform RE in patients with T2D. Future studies could be: 
1) A training study to determine how RE timing over a longer duration impacts 
clinical markers of glycemic control, such as HbA1c, or lipemic control, such as 
HDL-C, in patients with T2D.  
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2) A study to determine how RE at different times of the day impacts glycemic or 
lipemic control in patients with T2D (i.e. morning RE vs. afternoon RE vs. 
evening RE).  
3) A study to determine how RE at different times before or after a meal impacts 
postprandial glycemia and lipemia in patients with T2D (i.e. 30 min vs. 60 min vs 
1.5 h vs 2 h before or after a meal). 
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CHAPTER 5 - EXTENDED LITERATURE REVIEW 
This literature review will first describe the regulation of blood glucose, TAG, 
and glucoregulatory hormone concentrations in healthy and in patients with T2D. Then 
the links between abnormally high blood glucose and TAG concentrations and 
cardiovascular disease will be discussed. Lastly, the impact of AE and RE on metabolic 
control, gastric emptying, endocrine responses, and beta-cell function in non-diabetic and 
in patients with T2D will be discussed.  
Hormonal Regulation of Glycemia 
The regulation of postprandial glycemia is tightly controlled via hormones 
released from the intestine and endocrine pancreas. The endocrine pancreas secretes five 
different hormones including insulin, amylin, glucagon, somatostatin, and pancreatic 
polypeptide, but the hormones most critical for controlling blood glucose are insulin and 
glucagon. Insulin is secreted from the pancreatic β-cells in response to a meal and its 
functions include stimulating glucose uptake into skeletal muscle and adipose tissue [91], 
reducing hepatic glucose secretion [92], and increasing TAG hydrolysis by increasing 
adipose tissue lipoprotein lipase activity [93]. Insulin’s antagonist, glucagon, is secreted 
from pancreatic α-cells in response to hypoglycemia and its primary function is to 
stimulate hepatic glucose output [94].   
Both insulin and glucagon secretion are modulated by the gut derived incretin 
hormones GIP and GLP-1. GIP is secreted from endocrine K-cells of the duodenum and 
jejunum of the small intestine in response to macronutrient ingestion, and this hormone 
potentiates insulin secretion in a glucose dependent manner, inhibits glucagon secretion, 
and stimulates fatty acid synthesis and re-esterification in adipose tissue [95]. GLP-1 is 
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secreted predominately from endocrine L-cells located in the ileum and colon of the 
intestine in a biphasic manner in response to nutrient ingestion, and its functions include 
inhibiting gastric acid secretion and gastric emptying while stimulating insulin release in 
a glucose-dependent fashion [96].    
Gastric Emptying and Post-meal Glycemia 
It is now recognized that the rate of gastric emptying has a major influence on the 
postprandial glycemic response. The rate of gastric emptying is controlled by electrical 
slow waves generated by the interstitial cells of Cajal of the stomach. Gastric emptying is 
modulated by neural input and by the gut hormones GLP-1 [63-65] and cholecystokinin 
(CCK) [97]. The relationship between gastric emptying and glycemia was shown in a 
series of studies in which glucose was infused directly into the duodenum (to control 
gastric emptying) at different rates (i.e. between 1-4 Cal/min). In healthy young patients 
[98], healthy older patients, and patients with T2D [99], a higher rate of glucose infusion 
into the duodenum (2-4 Cal/min) resulted in significantly greater blood glucose 
concentrations compared to saline or 1 Cal/min glucose infusions. However, there was no 
difference in the glycemic response between the 2 and 4 Cal/min infusion, which likely 
occurred because of the much greater insulin response to counteract the hyperglycemia 
with a 4 Cal/min infusion. Gonlachanvit et al. [100] showed that accelerating gastric 
emptying with erythromycin infusion increased the postprandial glucose response, 
whereas slowing gastric emptying with morphine infusion lowered the postprandial 
glycemic response in T2D. In another study, reduced gastric emptying (mediated by i.v. 
infusion of GLP-1 prior to a meal), was associated with reduced postprandial glycemia 
and lipemia in healthy male volunteers [101]. Taken together, these studies show that 
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modulation of gastric emptying plays a role in determining the postprandial glycemic 
response. 
Impaired Hormonal Regulation of Glycemia in Type 2 Diabetics 
Impaired hormonal regulation of glycemia plays a major role in fasting and 
postprandial hyperglycemia in T2D [102]. There is evidence that, compared to healthy 
age, sex, and weight matched control subjects, patients with T2D are insulin resistant and 
have elevated rates of both endogenous and exogenous glucose release into circulation 
[103-108] in addition to impaired exogenous and endogenous glucose clearance [105-
106]. The latter is controversial as not all studies demonstrate impaired glucose clearance 
in T2D [107-108].  
In the early stages of T2D when insulin secretion in response to a meal still occurs 
(prior to β-cell failure), elevated fasting and postprandial glucose concentrations appear 
to be mediated by a combination of abnormalities including 1) hepatic insulin resistance 
resulting in failure of insulin to inhibit hepatic glucose release, gluconeogenesis, and 
glycogenolysis [108-110], 2) failure of glucagon suppression in the postprandial period, 
resulting in a lower insulin to glucagon ratio, which contributes to excessive endogenous 
glucose release and hepatic gluconeogenesis and glycogenolysis [108, 111], and 3) 
impaired ability of insulin to stimulate vasodilation in skeletal muscle [56], thus limiting 
postprandial blood glucose uptake in skeletal muscle which contributes to postprandial 
hyperglycemia in diabetes. In the later stages of T2D, insulin secretion from pancreatic β-
cells ceases (β-cell failure), and thus hypoinsulinemia contributes substantially to 
hyperglycemia in advanced T2D [112]. 
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In addition to impaired insulin and glucagon responses in T2D, there is also 
evidence that the incretin effect is impaired. For instance, patients with T2D have lower 
postprandial GLP-1 concentrations compared to non-diabetic obese patients after 
ingestion of a breakfast meal. This suggests that impaired GLP-1 responses contribute to 
delayed and blunted insulin responses and lack of suppression of postprandial glucagon 
in patients with T2D [113-115]. In support of this hypothesis, Vilsboll et al. [116] 
reported that GLP-1 infusion augmented late phase (20-120 min) insulin secretion in 
response to glucose in patients with T2D to a level comparable to non-diabetic patients. 
In contrast, GIP infusion did not alter late phase insulin secretion to glucose in patients 
with T2D, suggesting a defect in late phase amplification of insulin secretion by GIP 
[116]. In addition, the blunted GLP-1 response in T2D may contribute to the higher rates 
of gastric emptying in some of these patients, which may further worsen postprandial 
hyperglycemia [117-119]. However, the rate of gastric emptying in patients with T2D is 
highly variable, and in the later stages of T2D abnormally delayed gastric emptying or 
diabetic gastroparesis may exist. This delayed gastric emptying of a meal may contribute 
to postprandial hypoinsulinemia in these patients, although this hypothesis warrants 
further investigation.      
Consequences of Hyperglycemia  
Diabetes is an independent risk factor for vascular disease [120-121], and there is 
strong epidemiological and experimental evidence that hyperglycemia contributes to the 
increased risk of vascular disease with diabetes. For example, patients with type 1 
diabetes suffer from hyperglycemia due to a genetic defect in pancreatic β-cells resulting 
in inadequate insulin production, and these patients have much higher rates of 
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cardiovascular disease compared to age-matched non-diabetics [122-123]. In addition, 
other association studies have reported that postprandial hyperglycemia and glycemic 
peaks measured 2 h after a glucose load [124-130] are better predictors of cardiovascular 
disease in non-diabetic and diabetic patients compared to fasting blood glucose 
concentrations.   
The molecular mechanisms by which postprandial hyperglycemia promotes 
vascular disease are complex and involve several distinct but interrelated mechanisms. 
Nitric oxide (NO) is a gas molecule that is generated from the metabolism of the amino 
acid L-arginine by the enzyme endothelial NO synthase (eNOS). The function of NO is 
to relax smooth-muscle cells, which prevents leukocyte adhesion, platelet adhesion, and 
aggregation in the arterial wall [131]. There is evidence that chronic hyperglycemia 
impairs endothelial function in isolated aortas of animals [132-134] and in-vivo in 
humans [135-136]. Hyperglycemia inhibits the production of the vasodilator NO, thus 
reduced NO mediates some of the effects of hyperglycemia on endothelial function [137-
140].  
In addition, hyperglycemia impairs endothelial function by promoting an 
imbalance in oxidative stress and antioxidant defenses. There is in vitro [141] and in vivo 
[142-143] evidence showing that excessive oxidative stress impairs endothelial cell 
function in diabetes, and that the acute effects of hyperglycemia on endothelial 
dysfunction are blunted by antioxidants.  
Advanced glycosylation end products (AGE) are also responsible for the 
accelerated vascular disease in diabetes [144]. In the arterial walls, non-enzymatic 
reactions between glucose and proteins or lipoproteins result in the formation of AGE 
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which accelerate vascular disease via receptor independent and receptor dependent 
mechanisms. One of the most studied receptor independent mechanisms by which AGE 
promote atherosclerosis include the glycosylation of the apolipoprotein B [145] and 
phospholipid component of LDL [146], which alters the function of LDL and makes it 
more susceptible to oxidation, thus increasing its atherogenicity. The receptor dependent 
effects of AGE are mediated through the AGE receptor (RAGE). Research has shown 
that AGE interaction with RAGE on endothelial cells increases oxidative stress [147-148] 
while reducing endothelial barrier function and increasing endothelial barrier 
permeability [149]. This allows more lipid entry into the subendothelium, which 
contributes to the fatty streak of atherosclerotic lesions, whereas blockade of the AGE–
RAGE interaction in diabetic mice suppressed the fatty streaks in complex atherosclerotic 
lesions [150].    
Hyperglycemia induced increases in inflammatory molecules may also contribute 
to the increased risk of vascular disease in patients with T2D. Hyperglycemia has been 
shown to activate vascular smooth muscle nuclear factor of activated t-cells (NFAT), a 
proinflammatory cytokine that exacerbates atherosclerosis and restenosis [151].  
Taken together, there is strong evidence that hyperglycemia plays a significant 
role in the increased risk of vascular disease in diabetes via multiple different 
mechanisms. Thus, the main goal in the treatment of T2D includes lowering blood 
glucose levels.   
Regulation of Triacylglyceridemia 
The majority of TAG in circulation are bound to lipoproteins [84]. Exogenous 
TAG from the diet are not absorbed as TAG but are first digested by gastric lipases into 
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fatty acids and monoglycerides, particles that are more readily absorbed in the proximal 
jejunum and some distal parts of the small intestine [152]. Once in an enterocyte, the 
absorbed fatty acids and monoglycerides are re-synthesized into triacylglycerol’s and 
incorporated into a chylomicron lipoprotein and secreted into intestinal lymph and 
eventually the blood [152]. In humans, the chylomicron particle is very large, has a lower 
density compared to other lipoproteins, and is composed primarily (80-95%) of 
triacylglycerol [84]. Chylomicrons in the blood are hydrolyzed into fatty acids by 
lipoprotein lipase in the capillary beds of adipose tissue and muscle and then taken up by 
the tissue [84].  
The other primary source of TAG in circulation is endogenous TAG secreted 
from hepatocytes as part of very-low density-lipoprotein (VLDL) particles [84]. These 
particles are much denser than chylomicrons but contain less TAG (roughly 55-80% of 
the particle is TAG) [84]. These TAG particles are assembled in the endoplasmic 
reticulum of hepatocytes, and the fatty acids that make up these TAG particles come from 
a combination of sources including free fatty acids from circulation and de novo 
synthesized fatty acids in the hepatocyte [84]. VLDL particles can be categorized into 
two subclasses including VLDL-1 and VLDL-2 [153]. VLDL-1 particles contain more 
TAG and are less dense (Svedberg flotation rate, Sf 60-400) compared to VLDL-2 
particles (Sf 20-60), which contain more cholesterol [153]. Interestingly, VLDL TAG are 
cleared via the same lipolytic pathway as chylomicron TAG (i.e. via lipoprotein lipase), 
although lipoprotein lipase has a much greater affinity for chylomicron TAG than VLDL 
TAG [154].  
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The TAG in circulation can also be bound to intermediate density lipoproteins, 
low density lipoproteins, high density lipoproteins, or as free TAG [84]. However, it is 
thought that these TAG concentrations are relatively low compared to chylomicron and 
VLDL TAG [84].        
Hormones play a role in the regulation of plasma TAG concentrations. For 
instance, insulin has been shown to increase lipoprotein lipase activity in adipose tissue 
[93] and inhibit its activity in skeletal muscle [155], thus affecting the distribution and 
clearance of TAG from circulation into tissues. The incretin hormone GIP has been 
shown to increase adipose tissue lipoprotein lipase activity [156]. In the liver, acute 
insulin infusion inhibits VLDL-1 secretion but has no effect on VLDL-2 secretion [157]. 
Estrogen treatment in post-menopausal women has been shown to stimulate VLDL-1 
secretion [158].            
Consequences of Hypertriacylglyceridemia 
Although T2D is characterized by hyperglycemia, these patients are dyslipidemic 
as well and have elevated postprandial TAG concentrations [48]. Epidemiological studies 
suggest that elevated non-fasting TAG levels are associated with increased risk of 
myocardial infarction, ischemic heart disease or stroke, and death in men and women 
[159-162]. Mechanistic studies show that elevated postprandial TAG concentrations, 
primarily due to elevated VLDL TAG concentrations [163], increase the risk of 
cardiovascular disease via direct and indirect mechanisms. Excessive TAG 
concentrations directly interfere with the function of progenitor cells [164], induce 
apoptosis in endothelial cells [165], increase inflammation [165], increase circulating 
endothelial cell microparticles [166], and reduce endothelial function [167], all processes 
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that contribute directly to cardiovascular disease. In addition, excessive TAG 
concentrations suppress the protective effect of high-density lipoprotein cholesterol 
[168]. Thus, in addition to hyperglycemia, hypertriacylglyceridemia contributes to the 
increased risk of vascular disease in T2D.   
Acute Aerobic Exercise and Glycemic Control in Type 2 Diabetes 
Aerobic exercise has traditionally been the exercise mode prescribed to patients 
with T2D. To my knowledge, Larsen et al. [53] published the first study examining how 
acute AE impacts postprandial blood glucose in response to a mixed meal in T2D. In this 
study nine patients with T2D completed three testing trials including an exercise trial, a 
no exercise trial, and a caloric restriction trial. During the exercise and no exercise trials, 
the participants consumed a standardized breakfast meal and 4 h later a standardized 
lunch. During the exercise trial the participants performed 45 min of cycling exercise at 
~53% of VO2max beginning 45 min after the breakfast meal, while during the no 
exercise trial the participants remained sedentary the entire time. During the caloric 
restriction trial the caloric content of the breakfast meal was reduced to match the energy 
deficit of the exercise bout. Both exercise and caloric restriction reduced the postprandial 
glucose, insulin, and c-peptide response after the breakfast meal to a similar extent, but 
had no effect on the postprandial glucose, insulin, or c-peptide responses to the lunch 
meal. Larsen et al. [53] hypothesized that the reason why postprandial glucose levels 
were not reduced after lunch was because skeletal muscle glycogen levels were not 
depleted (although they did not measure this) during the moderate intensity exercise bout. 
Therefore, to determine if skeletal muscle glycogen depletion is required to reduce 
postprandial glucose after a lunch meal, Larsen et al. [54] performed another study to 
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determine if high intensity interval exercise (known to deplete glycogen) would reduce 
postprandial glucose after breakfast and after lunch. The design of the study was similar 
to their first study [53], except high intensity interval exercise was performed instead of 
moderate intensity exercise. The researchers found that despite 27% lower vastus lateralis 
muscle glycogen levels after high intensity interval exercise, compared to no exercise, the 
exercise bout only reduced the postprandial glucose, insulin, and c-peptide response to 
the breakfast meal, but not the lunch meal. Thus, it appears that factors other than skeletal 
muscle glycogen depletion modulate the exercise induced reduction in postprandial 
glycemia, at least in the acute exercise bout model. Subsequent studies following these 
also showed that acute AE reduces postprandial glucose concentrations. For instance, 
Poirier et al. [46] demonstrated that 60 min of  cycling at ~60% of VO2max reduced 
plasma glucose concentrations after a meal. In another study, walking for 20 min at a 
self-selected pace reduced the postprandial glucose response in patients with T2D [47].  
The studies cited previously assessed the effect of exercise on postprandial 
glucose after one or two meals in a laboratory setting. Although these studies nicely 
demonstrated that exercise reduces postprandial glycemia, understanding the impact of 
exercise on 24 h blood glucose homeostasis outside of the lab in patients during free 
living conditions would be advantageous and have more practical significance for the 
“real world”. The continuous glucose monitoring system (CGMS) is a sensitive tool that 
is inserted subcutaneously into the abdomen of users and continuously measures blood 
glucose every 5 min. The CGMS assesses 24 h blood glucose outside of the lab during 
free-living conditions. The first study to utilize the CGMS to assess the effect of exercise 
on 24 h blood glucose profiles in patients with T2D was performed by Praet et al. [169]. 
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In men with insulin treated T2D, 45 min of exercise (consisting of both AE and RE) 
reduced the daily prevalence of hyperglycemia by 39% (hyperglycemia defined as blood 
glucose > 180 mg/dL). In a subsequent study from the same lab, Manders et al. [170] 
assessed how AE intensity impacts 24 h blood glucose concentrations in patients with 
T2D. In males with non-insulin treated T2D, 60 min of low intensity cycling exercise 
(35% of max W) significantly reduced the prevalence of daily hyperglycemia by 50%. 
Although high intensity cycling exercise (30 min at 70% of max W) reduced the 
prevalence of daily hyperglycemia by 19%, this decline was not significant. Similarly, 45 
min of moderate intensity cycling (50% of maximum workload capacity) reduced the 
prevalence of daily hyperglycemia by 33% in impaired glucose tolerant and non-insulin 
and insulin treated patients with T2D [50]. Another study showed similarly findings, such 
that a single bout of moderate-intensity cycling reduced daily hyperglycemia by an 
average of 31% in non-insulin and insulin treated patients with T2D, although the 
response was highly variable among patients [171].   
It is clear that acute AE reduces post-meal glucose concentrations and improves 
24 h glycemic control but the response is highly variable. It is not clear how many meals 
after an acute exercise bout that exercise induced reductions in post-meal glucose 
concentrations persist. Thus, to determine how a single exercise bout performed in the 
morning before breakfast alters post-meal glucose concentrations to each subsequent 
meal over the next 2 d, Oberlin et al. [172] had patients with T2D perform 60 min of 
moderate intensity AE (60-75% of heart rate reserve) prior to breakfast, and measured the 
post-meal glucose response to 6 subsequent meals (3 each day). Exercise lowered the 24 
h average blood glucose concentrations, compared to the no exercise trial, and only 
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significantly lowered the post-meal glucose response to the lunch meal on day 1. Thus, 
the researchers suggested that daily exercise may be most effective in improving post-
meal glucose concentrations in type 2 diabetics.    
Although daily exercise is often promoted, no study has assessed how daily vs. 
every other day exercise impacts postprandial hyperglycemia in patients with T2D. To 
address this question, van Dijk et al. [173] designed a study to assess 48 h blood glucose 
control in patients with T2D that performed either 30 min of cycling (50% of max W)  
every day or 60 min of cycling every other day. The researchers reported that both 
exercise regimens reduced daily hyperglycemia by ~8% over the 48 h glucose monitoring 
period.  
Activities of daily living have also been shown to improve glycemic control in 
patients with T2D. Over a 24 h period, breaking up prolonged sitting with activities of 
daily living reduced the glucose area under the curve to breakfast, lunch, and dinner by 
~17% compared to no exercise [174]. However, one bout of moderate intensity exercise 
was much more effective, and reduced the glucose area under the curve to breakfast, 
lunch, and dinner by ~35% compared to no exercise [174]. Thus, structured exercise is 
better at improving glycemic control than simply increasing activities of daily living, 
although benefits can be achieved from both strategies.  
Lack of time is frequently cited as a barrier to exercise. Thus, high intensity 
interval training (HIT) has been gaining popularity because of its short duration, but the 
effect of HIT on 24 h glycemic control in patients with T2D has not been well 
established. Gillen et al. [175] assessed how HIT training (10 x 60 s cycling efforts at 
~90% of max HR) alters 24 h glycemic control in patients with T2D. These researchers 
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reported that daily hyperglycemia was reduced by ~10% and postprandial glucose 
excursions were reduced by ~36% compared to no exercise.  
Blood Glucose Kinetics during Exercise 
In the fasted state, during AE glucose uptake in contracting skeletal muscle 
increases, but blood glucose concentrations remain relatively unchanged because of the 
simultaneous increase in hepatic glucose output that closely matches any increase in 
skeletal muscle glucose uptake in healthy non-diabetic patients [176-177]. On the 
contrary, in the fasted state in patients with T2D the increase in skeletal muscle glucose 
uptake during AE is not equally matched by an increase in hepatic glucose production, 
thus during AE blood glucose concentrations decrease [177]. It is not known if this same 
response occurs with RE, an activity that does not require continuous muscle 
contractions. 
Acute Resistance Exercise and Glycemic Control in Type 2 Diabetes 
Aerobic exercise is often promoted to improve glycemic control in T2D, but RE 
has been gaining popularity as an alternative or complement to traditional AE. Only a 
few studies have examined the direct impact of acute RE on glycemic control or insulin 
sensitivity in patients with T2D. Fenicchia et al. [49] demonstrated that a single whole 
body RE session performed 12 to 24 h prior to an oral glucose tolerance test did not alter 
fasting glucose or insulin values but reduced the postprandial glucose response in patients 
with T2D. Similarly, Gordon et al. [68] showed no change in fasting blood glucose or 
insulin concentrations 24, 48, or 72 h after an acute RE session in patients with T2D. On 
the contrary, in pre-diabetic patients, acute RE lowered fasting blood glucose and insulin 
concentrations in a dose and intensity dependent manner [69]. These prior studies are 
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limited as only a fasting blood glucose measure was taken or postprandial glucose was 
assessed after an oral glucose tolerance test, a common diagnostic test that is really not 
physiologically relevant. van Dijk et al. [50] was the first to examine how an acute bout 
of RE and AE impacts glycemic control with a mixed meal diet in patients with T2D. 
These researchers reported that 45 min of heavy RE (four exercises, three to five sets, 10 
repetitions, 75% of 1-RM) significantly reduced 24 h average blood glucose 
concentrations. In addition, the acute RE bout reduced daily hyperglycemia by 35%, an 
effect that was similar to 45 min of AE (cycling at 50% maximal power output).  
However, not all studies suggest that acute RE improves glycemic control in 
patients with T2D. For instance, Fluckey et al. [38] demonstrated that an acute bout of 
whole body RE performed ~18 h prior to a 75 g OGTT did not alter postprandial glucose 
concentrations but significantly reduced postprandial insulin concentrations in patients 
with T2D. Bacchi et al. [39] performed a study examining 48 h blood glucose profiles 
(assessed with a CGMS) in patients with T2D. After four months of either resistance 
training (three sessions per week, nine exercises, 10-12 repetitions at 30-50% of 1-RM) 
or AE training (three sessions per week, 60 min per session, 60-65% of HRR), 48 h blood 
glucose profiles were measured with a CGMS in patients that performed a single, 60 min 
bout of exercise. During the 60 min acute exercise bout, blood glucose concentrations 
were significantly lower during AE, but not RE. Over the entire 48 h testing period, blood 
glucose concentrations were similar between no exercise, AE, and RE conditions. Given 
the mixed findings between studies that have examined the impact of an acute session of 
RE on glycemic control in patients with T2D, more research is warranted.  
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Exercise and Gastric Emptying 
Most studies examining how exercise alters gastric emptying were performed in 
healthy young patients and utilized a carbohydrate solution. These studies demonstrate 
that AE inhibits gastric emptying in an intensity dependent manner. For instance, Leiper 
et al. [66] demonstrated that high intensity cycling at 66% or 75% of VO2max reduced 
gastric emptying by ~15% and ~36%, respectively, compared to no exercise, in healthy 
men. Similarly, high intensity running slowed gastric emptying of a placebo solution and 
carbohydrate solution by ~47% and 29%, respectively, compared to low intensity 
walking in healthy men [67].  
The impact that exercise has on gastric emptying in relation to postprandial 
glycemia has not been studied extensively. Gill et al. [178] demonstrated that 90 min of 
walking at 60% VO2max the day prior to an oral fat tolerance test did not alter gastric 
emptying or postprandial glucose concentrations. Published observations from our lab 
show that 60 min of walking at 55-60% of VO2peak the day prior to a meal did not alter 
postprandial glucose, GLP-1, or GIP concentrations in lean or obese patients [179]. The 
fact that GLP-1, GIP, or glucose was not different between trials in our study suggests 
that gastric emptying was unaltered (although gastric emptying was not directly 
measured). These two studies are limited by the fact that the exercise bout was performed 
the day prior to ingestion of a meal. The impact that exercise has on postprandial gastric 
emptying and how it relates to postprandial glycemia when the exercise bout is 
performed in closer proximity to a meal has been studied by only one investigator. 
Enevoldsen et al. [180] studied lean healthy men (n = 7) who performed 60 min of 
moderate intensity cycling beginning 90 min prior to a meal during one trial or 60 min 
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after a meal during the other trial. It was reported that gastric emptying (assessed with 
acetaminophen) was similar between trials. However, this study has several limitations 
including 1) A no exercise trial was not used to compare with the two exercise trials, 2) 
the exercise bout was performed 60 min after the meal, 45 min after the acetaminophen 
peak in this study and at time when most of the meal has already been emptied from the 
stomach, 3) infrequent blood sampling thus the resolution of the change in the 
acetaminophen response was not clear, and 4) a small sample size was used.  
Only one study has examined how AE alters gastric emptying in patients with 
T2D. In this study, long standing insulin dependent diabetics with diabetic gastroparesis 
(impaired gastric emptying) ingested a meal while gastric emptying was measured. The 
30-min walking session started 90 min after ingestion of the meal. Gastric emptying was 
measured during the 90 min after ingestion of the meal and again 20 min after cessation 
of the walk. The researchers reported that walking increased gastric emptying in some 
patients (7/50), but had little effect on gastric emptying in most of the participants [181]. 
This study was limited by the fact that gastric emptying was measured after the meal had 
been emptied from the stomach and after the walking session. It is not known how gastric 
emptying of a mixed meal is altered when RE is performed either immediately before or 
soon after a mixed meal in patients with T2D. 
Exercise and Post-meal Incretin Hormone Responses 
Acute Exercise 
The majority of research examining the impact of acute exercise on postprandial 
incretin hormone responses has utilized a non-diabetic population. Previous observations 
from our lab indicate that 1 h of moderate intensity AE the night prior to a mixed meal in 
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the morning reduced the postprandial insulin and TAG response in obese patients, and 
these changes occurred without changes in postprandial GLP-1 and GIP responses [182]. 
Using a similar study design, Dekker et al. [183] reported that 1 h of moderate intensity 
AE in hypertriacylglycerolemic obese men the day before a morning oral fat tolerance 
test did not alter postprandial GIP or GLP-1 concentrations. These studies suggest that 
when exercise is performed the day prior to a mixed meal postprandial incretin hormone 
concentrations are not altered.  
On the contrary, other studies have shown that acute AE performed immediately 
prior to or after ingestion of a meal can alter postprandial incretin hormone responses. 
For instance, in trained athletes that performed 2 h of moderate intensity AE immediately 
prior to oral glucose ingestion, the postprandial insulin and GIP response, but not the 
GLP-1 response, was attenuated [184]. Similarly, in trained male athletes prior 
exhaustive AE reduced postprandial GIP responses after glucose ingestion [185]. These 
studies suggest that prolonged AE prior to ingestion of an oral glucose tolerance test 
reduces postprandial GIP responses. However, when the timing of the exercise bout is 
moved to after meal ingestion, research has shown that moderate or high intensity AE 
augments the postprandial GLP-1 response in non-diabetic patients [62, 186-187]. Thus, 
the timing of exercise around a meal has an impact on the postprandial incretin hormone 
response in healthy patients.  
The effect of acute AE on postprandial incretin hormone responses in patients 
with T2D has only been assessed by one investigator. After 28 days of metformin or 
placebo treatment, AE performed prior to a lunch meal did not alter postprandial GLP-1 
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or GIP responses [86]. However, metformin did increase preprandial GLP-1 and GIP and 
postprandial GLP-1 concentrations.   
Exercise Training   
       Three cross sectional studies have compared postprandial GIP and GLP-1 responses 
in trained vs. untrained subjects, and the responses seem to depend on the type of test 
meal given. In the study by Lund et al. [188], after ingestion of a mixed meal shake 
postprandial GIP responses were lower in aerobically trained compared to untrained 
patients, while postprandial GLP-1 responses were similar between the groups. However, 
fasting GLP-1 concentrations were higher in aerobically trained patients. Interestingly, 
these same researchers demonstrated in another study employing an oral glucose 
tolerance test that insulin secretion, but not postprandial GLP-1 or GIP concentrations, 
were lower in trained vs. untrained patients. Similarly, Weiss et al. [189] reported that 
postprandial insulin responses, but not GIP or GLP-1 responses, were lower in 
aerobically trained vs. untrained patients after consumption of a 75 g oral glucose 
tolerance test. Taken together, postprandial GIP responses are lower in trained vs. 
untrained patients after a mixed meal, while postprandial GIP responses after an oral 
glucose tolerance test are not different between trained and untrained non-diabetic 
patients.     
 Only one study has assessed how exercise training impacts postprandial GIP 
responses in type 2 diabetics. After exercise and diet-induced weight loss (~ 5.0 kg), the 
postprandial GIP response was higher in obese type 2 diabetic subjects, and this was 
associated with increased insulin secretion and improved beta-cell function [190].   
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Exercise and Beta-cell Function 
Acute or Short Term Aerobic Exercise and Beta-cell Function 
To date, only one study has examined how short-term AE alters beta-cell 
function. The first study to do so reported that 7 d of moderate intensity AE (1 h/d) 
increased the disposition index (measure of beta cell function) by 31% in older patients 
with impaired glucose tolerance [191]. No study has assessed how acute AE or RE alters 
beta-cell function in patients with T2D.   
Exercise Training and Beta Cell Function 
  The majority of studies show that AE training improves beta-cell function in non-
diabetic and diabetic adults. For instance, Slentz et al. [192] reported that an 8-month 
exercise program with either moderate or vigorous exercise intensities improved the 
disposition index (measure of beta-cell function) in overweight adults, with moderate 
intensity exercise having the biggest impact. Similarly, Malin et al. [193] reported that an 
exercise training and weight loss intervention improved the disposition index in older 
patients with pre-diabetes. Further, the increase in the disposition index due to exercise 
training occurred in a linear dose-response manner such that higher exercise doses (> 
2,000 kcal/wk) improved beta-cell function more so than lower exercise doses. This same 
group also showed that an exercise and diet-induced weight loss program in patients with 
T2D improved beta-cell function, and that this was associated with increased glucose 
stimulated GIP concentrations [190]. Interesting, diet composition influences the effect of 
an exercise-training intervention on beta-cell function. For example, Solomon et al. [194] 
reported that a low-GI diet did not alter beta-cell function after an exercise and diet 
induced weight-loss intervention, whereas a high-GI diet impaired beta-cell function 
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during a similar intervention, despite similar reductions in weight and improvements in 
insulin sensitivity occurred during both dietary interventions. Resistance training has also 
been shown to improve beta-cell function. Croymans et al. [87] demonstrated that a 12-
wk resistance training program (3 RE sessions per wk) improved beta-cell function in 
overweight/obese, sedentary young men.   
 Not all studies suggest that AE or RE improves beta-cell function. For instance, 
resistance training performed twice weekly for 16-wks did not alter beta-cell function in 
overweight adolescent Latinos [88]. Similarly, Bacchi et al. [89] demonstrated four 
months of AE or RE did not alter beta-cell function in patients with T2D.       
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APPENDIX A 
 
CONSENT FORM TO PARTICIPATE IN A RESEARCH STUDY 
 
INVESTIGATOR’S NAME: DR. JILL A. KANALEY    
PROJECT #  1208507 
 
STUDY TITLE: EXERCISE TIMING AND POSTPRANDIAL GLYCEMIA IN TYPE 2 DIABETES 
 
INTRODUCTION 
 
This consent may contain words that you do not understand.  Please ask the 
investigator or the study staff to explain any words or information that you do not 
clearly understand. 
 
This is a research study. Research studies include only people who choose to participate.  
As a study participant you have the right to know about the procedures that will be used 
in this research study so that you can make the decision whether or not to participate.  
The information presented here is simply an effort to make you better informed so that 
you may give or withhold your consent to participate in this research study.   
 
Please take your time to make your decision and discuss it with your family and friends. 
 
You are being asked to take part in this study because you have type 2 diabetes (T2D).  
 
In order to participate in this study, it will be necessary to give your written consent. 
 
WHY IS THIS STUDY BEING DONE? 
 
The purpose of this study is to determine how the timing of resistance exercise around a 
dinner meal (before dinner vs. after dinner) alters blood glucose levels, hormonal 
responses, and gastric emptying in patients with T2D. 
Patients with T2D have abnormally high blood glucose levels after a meal, and prior 
research has shown that exercise can help lower blood glucose levels after a meal. The 
current exercise guidelines for patients with T2D does not include the best time, relative 
to a meal (either before or after a meal), an individual with T2D should exercise to get the 
most benefit on their blood glucose levels. Thus, the scientific reason for doing this study 
is to determine if there is an optimal time for an individual with T2D to exercise to lower 
the blood glucose response to a meal.    
 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
 
About 15 people will take part in this study at the University of Missouri.   
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WHAT IS INVOLVED IN THE STUDY? 
 
Visit 1 – Screening (~30 min): You will need to come in initially to have some tests done 
to determine your eligibility for the study.  At this visit you will: 
 Review and sign the consent form. 
 Height, weight and blood pressure measurement 
 Fasting glucose levels and HbA1c: We will ask you to come in after an overnight 
fast to the Exercise Physiology Lab in McKee Gym to have your fasting blood 
glucose checked in the morning, as well as get a measure of your HbA1c.  This 
will be done by getting a blood sample by finger stick.   
 Complete a health inventory questionnaire.   
You will be told at the end of the screening if you qualify or not. In order to participate in 
this study, you will need to receive permission from your physician to exercise.  
 
Visit 2 - Resting energy expenditure (REE), body composition (BODPOD), and 
familiarization session one.  
You will need to overnight fast for ~10 h prior to Visit 2.  This testing will be in the 
morning period.  
REE: During the REE, you will lay supine in a recliner for 30 min while all expired air is 
collected in a canopy that will be placed over your head and analyzed for O2 and CO2 
content. You will be able to breathe room air normally during the procedure. Expired air 
will be collected and analyzed in the machine. 
Body Composition: In this test we will measure your percent body fat using the BOD 
POD.  In this test you will wear a bathing suit (or tight fitting shorts/T-shirt) and sit in 
capsule quietly while the machine makes the measurement. The BOD POD is like a large 
bubble about 5’ high and 4’wide with a window in it.  We ask you to sit quietly inside the 
Pod, while we make the measures of how much space you take up in the BOD POD.  
You will then be asked to puff gently through a tube a few times so we can determine 
how much air is in your lungs.  During this test you will not feel anything and you should 
not feel any anxiety about sitting in the BOD POD as there is a window and you can the 
investigator during the testing. This part of the testing takes about 10 minutes. 
Familiarization session one: This session will be used to teach you how to properly 
perform each exercise. The weight for the resistance exercises will be light (~10-40% of 
bodyweight) and you will perform four sets of 10 repetitions with a 1 min rest period 
between each set of the following exercises (performed in this order): 1) Leg Press, 2) 
Calf Raises, 3) Chest Flyes, 4) Back Flyes, 5) Back Extensions, 6) Shoulder Raises, 7) 
Hamstring Curls, and 8) Abdominal Crunches.   
 
Visit 3 - Strength Testing 
There will be at least a 3 d break after the first exercise session, and after this you will 
report back to the lab. Your 10 repetition max (10-RM) will be determined for each 
exercise. The 10-RM is the maximum amount of weight that you can lift 10 times. 
During this session, each exercise will begin with a warm-up set (~10-40% of 
bodyweight), and then for each subsequent set weight will be progressively added until 
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the 10-RM for the exercise is determined.  At least 2 min of rest will be allowed between 
each 10-RM attempt. 
Visit 4 - Familiarization session two.  
Following a 3 d break, you will report back to the lab. On this visit, you will perform four 
sets (1 min rest between sets) of 10 repetitions of the exercises described previously. The 
first set for each exercise will be a warm-up set and the weight used will be 50% of your 
10-RM. After the warm-up set, the weight for the next three sets will be 80% of your 10-
RM.  
 
Visits 5-13: You will complete three different trials. Each trial will be 3 days in length 
and separated by at least 1 week. The three trials will include 1) a no exercise trial, 2) 
exercise before dinner, and 3) exercise after dinner.  
Day 1: During the evening of day one of each trial (1800 h) you will report to the lab and 
a continuous glucose monitor system (CGMS) will be inserted and you will be trained on 
how to take and record a finger stick blood glucose measure. You will be given 
prepackaged study meals and will be instructed on when to eat the meals. 
 The CGMS allows us to gain information about how your blood sugar levels 
change over the course of a day in a free living setting. The CGMS is worn on 
your abdomen and it is a tiny glucose sensor which is inserted just under the skin. 
We will clean the area, and then a small tube (catheter) ~1/2 the size of a sewing 
needle will be placed under your skin. The insertion is quick, and is usually not 
painful. The tube is attached to a wire connected to a small device approximately 
the size if a silver dollar, and this device measures and records your blood glucose 
values throughout the day. Tape holds everything in place. In addition, you will 
be asked to make at least four finger stick blood glucose readings with a standard 
glucose meter at different times each day.  The monitor will be removed after 
testing.  Any exercise engaged in, and meals or snacks consumed are also entered 
into a paper-based diary.  After the first time you wear the CGMS, we will ask 
you to repeat the timing, content and quantity of food consumption to match your 
first visit.   
 
Day 2: You will eat the prepackaged meals at the scheduled times on your own in the 
morning and afternoon. Prior to each meal, you will take and record a finger stick blood 
glucose measure.  
This day will last ~ 6 hr.   
 You will arrive at 4:15 pm, and return your food containers.  
 Height, weight and resting blood pressure will be measured.   
 A small catheter will be placed in the forearm vein so that we can draw blood 
samples. This catheter will be attached to an IV of saline water which will keep 
this line open after each blood sample.  This allows us to take multiple blood 
samples but not have to stick you repeatedly. This remains in your arm until 10 
pm.     
 Appetite ratings will be taken throughout the study evening. 
 You will consume a dinner at 6 pm, and will be given 20 min to eat the meal. 
Acetaminophen will be ground up and put into the spaghetti sauce of the dinner 
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meal so that gastric emptying can be measured. You will not be able to taste the 
acetaminophen. 
 No exercise trial:  you will remain physically inactive during the time you are in 
the lab. 
 Exercise trial 1:  ~45 min of resistance exercise will be performed between 4:45 -
5:30 pm 
 Exercise trial 2:  ~45 min of resistance exercise will be performed 30 min after 
completing dinner. 
 The order of these 3 trials will be randomized. 
 Energy expenditure will be measured using the metabolic cart between 1645-1750 
h, 1850 – 1935 h, and 2100-2130 h.   
 Blood samples will be taken throughout the evening.  You can drink as much 
water as you like during this study day.  You will sit quietly during the day and 
can read, watch DVDs, etc. except when testing for energy expenditure. During 
this testing you must remain still and it must be quiet or you will be exercising.     
 
Day 3: You will report back to the lab at ~0800 h and a fasting blood sample will be 
taken and you will be given breakfast.    
How Long Will I Be in the Study? 
The study will take at least 5 weeks to complete.  
You can stop participating at any time.  Your decision to withdraw from the study 
will not affect in any way your medical care and/or benefits.   
 
WHAT ARE THE RISKS OF THE STUDY? 
Risks of body composition: The BODPOD is safe, although you may experience 
claustrophobia. A window is built into the machine that allows you to look outward to 
help avoid the feeling of claustrophobia and there is a release button on the inside of the 
machine should you feel like you must get out. 
Risks of blood sampling: May cause fainting and some discomfort and/or bruising at the 
site on the arm where the blood was taken. Rarely an infection occurs at the blood 
drawing site. There is also a risk of a blood clot forming in the vein and a risk of 
developing anemia.  
Risks of acetaminophen: You will be given a dose of acetaminophen mixed in with the 
dinner meal (2 g which will be grounded up and added into the spaghetti sauce for the 
dinner). This dose of acetaminophen will not exceed the daily recommended dose of 4-5 
g. Risks of acetaminophen administration are rare but can include nausea, vomiting, and 
at high repeated doses liver or kidney damage.  Thus, you should not consume over-the-
counter or prescription medications containing acetaminophen the day before or the day 
after the study.  Over-the-counter medications to avoid include: Tylenol, Exedrin PM, 
Alka Seltzer Plus Cold, TheraFlu cold medicine, while prescription medications for pain 
include Vicodin and Percocet.  
Risks of resistance training: Resistance training may cause skeletal muscle soreness. This 
is not permanent and will resolve within a few days. 
CGMS Glucose monitoring: There is a small risk of infection, bruising or nausea 
associated when using the CGMS.  To minimize risk, the placement of the CGMS is 
performed with sterile techniques by qualified personnel in the Exercise Physiology Lab. 
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ARE THERE BENEFITS TO TAKING PART IN THE STUDY? 
The data generated from this project will be useful for patients with type 2 diabetes and 
will highlight the best time to perform exercise to lower their blood glucose responses 
after dinner. Potentially this study may motivate some subjects to start exercising in the 
evening. 
 
WHAT OTHER OPTIONS ARE THERE? 
The alternative is to not participate in this study. 
 
WHAT ABOUT CONFIDENTIALITY? 
Information produced by this study will be stored in the investigator’s file and identified 
by a code number only.  The code key connecting your name to specific information 
about you will be kept in a separate, secure location.  Information contained in your 
records may not be given to anyone unaffiliated with the study in a form that could 
identify you without your written consent, except as required by law.  If the investigator 
conducting this study is not your primary, or regular doctor, she must obtain your 
permission before contacting your regular doctor for information about your past medical 
history or to inform them that you are in this trial. 
 
It is possible that your medical and/or research record, including sensitive information 
and/or identifying information, may be inspected and/or copied by the study sponsor 
(and/or its agent), the Food and Drug Administration (FDA), federal or state government 
agencies, or hospital accrediting agencies, in the course of carrying out their duties.  If 
your record is inspected or copied by the study sponsor (and/or its agents), or by any of 
these agencies, the University of Missouri will use reasonable efforts to protect your 
privacy and the confidentiality of your medical information. 
 
The results of this study may be published in a medical book or journal or used for 
teaching purposes.  However, your name or other identifying information will not be used 
in any publication or teaching materials without your specific permission.   
 
WHAT ARE THE COSTS? 
The only cost to you may be transportation to/from our research laboratory.  
 
WILL I BE PAID FOR PARTICIPATING IN THE STUDY? 
You will be compensated $180.00 for completion of this study.   
If you do not complete the study days and drop out, you will be paid $7/hr for the time 
you put in. 
 
WHAT IF I AM INJURED? 
It is not the policy of the University of Missouri to compensate human subjects in the event 
the research results in injury.  The University of Missouri, in fulfilling its public 
responsibility, has provided medical, professional and general liability insurance coverage 
for any injury in the event such injury is caused by the negligence of the University of 
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Missouri, its faculty and staff.  The University of Missouri also will provide, within the 
limitations of the laws of the State of Missouri, facilities and medical attention to subjects 
who suffer injuries while participating in the research projects of the University of Missouri.  
In the event you have suffered injury as the result of participation in this research program, 
you are to contact the Risk Management Officer, telephone number (573) 882-1181, at the 
Health Sciences Center, who can review the matter and provide further information.  This 
statement is not to be construed as an admission of liability. 
 
WHAT ARE MY RIGHTS AS A PARTICIPANT? 
Participation in this study is voluntary.  You do not have to participate in this study.  
Your present or future care will not be affected should you choose not to 
participate.  If you decide to participate, you can change your mind and drop out of the 
study at any time without affecting your present or future care in the University of 
Missouri hospital. Leaving the study will not result in any penalty or loss of benefits to 
which you are entitled. In addition, the investigator of this study may decide to end your 
participation in this study at any time after she has explained the reasons for doing so and 
hashelped arrange for your continued care by your own doctor, if needed. You will be 
informed of any significant new findings discovered during the course of this study that 
might influence your health, welfare, or willingness to continue participation in this 
study. 
 
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
If you have any questions regarding your rights as a participant in this research and/or 
concerns about the study, or if you feel under any pressure to enroll or to continue to 
participate in this study, you may contact the University of Missouri Health Sciences 
Institutional Review Board (which is a group of people who review the research studies 
to protect participants’ rights) at (573) 882-3181. You may ask more questions about the 
study at any time. For questions about the study or a research-related injury, contact Jill 
Kanaley, PhD at 573-882-2519. 
A copy of this consent form will be given to you to keep. 
 
SIGNATURE 
I confirm that the purpose of the research, the study procedures, the possible risks and 
discomforts as well as potential benefits that I may experience have been explained to 
me.  Alternatives to my participation in the study also have been discussed.  I have read 
this consent form and my questions have been answered.  My signature below indicates 
my willingness to participate in this study. 
 
          ____________ 
Subject/Patient*        Date 
 
SIGNATURE OF STUDY REPRESENTATIVE 
I have explained the purpose of the research, the study procedures, identifying those that 
are investigational, the possible risks and discomforts as well as potential benefits and 
have answered questions regarding the study to the best of my ability. 
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Study Representative****      Date 
 
****Study Representative is a person authorized to obtain consent.  Per the policies of 
the University of Missouri Health Care, for any 'significant risk/treatment' study, the 
Study Representative must be a physician who is either the Principal or Co-Investigator.  
If the study is deemed either 'significant risk/non-treatment' or 'minimal risk,' the Study 
Representative may be a non-physician study investigator.   
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Abstract 
 
Abnormally elevated postprandial glucose and triacylglycerol (TAG) concentrations are 
risk factors for cardiovascular disease in patients with type-2 diabetes. The most effective 
time to exercise to lower postprandial glucose and TAG concentrations is unknown. 
Thus, the aim of this study was to determine what time is more effective, either pre- or 
post-dinner resistance exercise (RE), at improving postprandial risk factors in patients 
with type-2 diabetes. Methods: Thirteen obese-patients with type-2 diabetes completed 
three trials in a random order in which they consumed a dinner meal with 1) no RE 
(NoRE), 2) pre-dinner RE (RE→M), and 3) post-dinner RE beginning 45-min after 
dinner (M→RE). Clinical outcome measures included postprandial glucose and TAG 
concentrations. In addition, postprandial acetaminophen (gastric emptying), endocrine 
responses, FFA, and beta-cell function (mathematical modeling) were measured to 
determine if alterations in these factors were related to changes in glucose and TAG. 
Results: The TAG incremental-AUC (iAUC) was ~92% lower (P<0.05) during M→RE 
compared to NoRE and RE→M, an effect due in part to lower VLDL-1 TAG 
concentrations. The glucose iAUC was reduced (P<0.05) by ~18% and 30% during the 
RE→M and M→RE trials, respectfully, compared to NoRE, with no difference between 
RE trials. RE→M and M→RE reduced the insulin iAUC by 35% and 48%, respectfully, 
compared to NoRE (P<0.05). The GLP-1 iAUC was ~50% lower (P<0.05) during 
M→RE compared to NoRE and RE→M. No other variables were different between 
trials. Conclusions: Post-dinner RE improves postprandial metabolic risk factors better 
than pre-dinner RE in obese patients with type-2 diabetes. 
 
105	
	
Key words: Exercise timing, glycaemic control, weight training, obesity, glucose 
metabolism, lipid metabolism  
Introduction 
Abnormally elevated postprandial glucose [1-3] and triacylglycerol (TAG) [4-6] 
concentrations are strong risk factors for cardiovascular disease (CVD) in patients with 
type-2 diabetes. Therefore, interventions that reduce postprandial glucose and TAG 
concentrations should lower the risk of CVD [7-8]. Acute exercise typically lowers 
postprandial glucose [9-19] and TAG concentrations [20] in patients with type-2 diabetes, 
but there is considerable heterogeneity in the responses with some individuals not 
experiencing beneficial changes in these risk factors [13, 21]. One potential explanation 
why some patients with type-2 diabetes do not have beneficial changes in postprandial 
glucose and TAG with acute exercise is because of the timing of the acute exercise 
session relative to a meal.  
Limited evidence suggests that the timing of aerobic exercise around a meal may 
be important and might explain why some individuals are exercise “insensitive” or “non-
responders”. The only study to directly compare pre-meal and post-meal exercise in 
patients with type-2 diabetes showed that post-dinner, but not pre-dinner walking, 
lowered postprandial glucose concentrations [22]. Although no study has directly 
examined the effect of exercise timing on postprandial TAG in patients with type-2 
diabetes, there is evidence that exercise performed the day prior to a high fat meal has no 
effect on postprandial TAG responses [21, 23], while post-breakfast aerobic exercise 
reduced the postprandial TAG response [20]. Taken together, it appears that aerobic 
exercise may have its most powerful effect to lower postprandial glucose and TAG 
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responses when performed after a meal, possibly because of reduced gastric emptying 
and/or greater skeletal muscle glucose and TAG uptake and utilization at this time.  
The aforementioned studies examined aerobic exercise, but no study, to our knowledge, 
has examined how resistance exercise (RE) timing relative to dinner alters postprandial 
glucose and TAG concentrations. From a practical perspective, many obese patients with 
type-2 diabetes may not enjoy or be able to perform aerobic exercise soon after a meal 
when the exercise session may have its most powerful effect to lower postprandial 
glucose and TAG concentrations. However, RE may be a practical alternative because it 
can be better tolerated in obese patients with type-2 diabetes because traditional RE 
consists of short work periods with long rests between sets. However, compared to 
aerobic exercise, RE is a different physiological stimulus (i.e. RE is anaerobic, does not 
involve continuous skeletal muscle contractions, and has lower energy expenditure), thus 
it is not clear if RE would alter postprandial glucose and TAG concentrations as robustly 
as aerobic exercise. Some studies report acute RE prior to meal(s) improves glycaemic 
control [18-19], while other studies report it does not [24-25], and no study has assessed 
how acute RE alters postprandial TAG concentrations. In addition, these studies assessed 
the effects of RE on postprandial glucose concentrations after a breakfast or lunch meal, 
and not a dinner meal later in the day, a time when glucose and TAG concentrations have 
been reported to be highest in patients with type-2 diabetes [26-27]. Therefore, the 
primary purpose of this study was to test the hypothesis that post-dinner RE, compared to 
pre-dinner RE, is more effective at improving two clinically important postprandial risk 
factors (glucose and TAG) for CVD at a time of day when they are typically highest in 
obese patients with type-2 diabetes. In addition, postprandial acetaminophen (gastric 
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emptying), endocrine responses, free fatty acids (FFA), and beta-cell function 
(mathematical modeling) were measured to determine if alterations in these factors were 
related to changes in postprandial glucose and TAG concentrations. Subjective well-
being was assessed to determine how feasible the different RE times were. 
Research Design and Methods 
Participants 
 
 The University of Missouri Health Science Institutional Review Board approved 
this study protocol and all participants provided written informed consent. Participants in 
this study were obese (body mass index > 30 kg/m2), physician diagnosed with type 2 
diabetes, receiving standard medical care, non-smokers, not using insulin, had no history 
of surgery for weight loss, refrained from performing exercise or going on any special 
diets while participating, and were weight stable. The participants took their medications 
at the usual dose, frequency, and time while participating in this study.  
Experimental Design  
 
Baseline testing included assessments of height, weight, body composition 
(assessed via BODPOD®), resting energy expenditure, physical activity energy 
expenditure, and familiarization and strength testing (described in detail later). After 
baseline testing, all participants completed three, 3 d trials in a random order. On day one 
a continuous glucose monitor (CGM) was inserted into the abdomen of the participant 
and the participants were instructed on how to take and record a finger stick blood 
glucose measure with a glucometer (Accu-Chek Compact Plus, Roche Diagnostics), 
which was used to calibrate the CGM. Following training, the participants were given 
their prepackaged study meals and were instructed on when to eat the meals the following 
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day. On day two, the participants ate the standardized breakfast and lunch on their own 
and immediately prior to each meal recorded a finger stick blood glucose measure. In the 
evening the participants reported to the lab for testing sometime between 3 – 5:30 p.m. 
and upon arrival a venous catheter was inserted into a forearm vein. The participants 
consumed a dinner meal in the lab with 1) no RE (NoRE), 2) pre-dinner RE (RE→M) 
ending ~20-30 min before dinner, or 3) post-dinner RE beginning 45 min after dinner 
(M→RE). On day three of all trials (between 6:30–8:30a.m.) and ~12–15 h after the RE 
session the participants reported to the lab overnight fasted and a fasting blood sample 
was taken, followed by consumption of a standardized breakfast meal. After the 
participants consumed breakfast they were allowed to leave the lab but were required not 
to consume any food for 4 h so that the 4 h postprandial glucose response to breakfast 
could be measured.  
Resistance Exercise 
 
 For baseline testing, each participant performed familiarization strength testing so 
that they were not naive to RE before the study. Participants completed the first 
familiarization to teach them how to properly perform each exercise. During this visit, the 
weight for RE was light (~10-40% of bodyweight) and the participants performed 1-2 
sets of 10-repetitions of the following exercises (in this order): Leg press, seated calf 
raises, seated chest flyes, seated back flyes, back extensions, shoulder raises, leg curls, 
and abdominal crunches. Within a week of this first visit, participants returned for 
strength testing and their 10 repetition maximum (10-RM) for each exercise described 
previously (except abdominal crunches) was determined. At least 3 d after 10-RM 
testing, a second familiarization was performed during which the participants performed 
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three sets (1-2 min rest between sets) of 10-repetitions. During this session, the first set 
for each exercise was a warm-up set and the weight used was 50% of the participants 10-
RM. After the warm-up set, the weight for the next two sets was the participants 
previously determined 10-RM. Following these visits, the participants completed the 
three study days and the RE session during the study days was identical to the protocol 
for the second familiarization session.     
Diet 
 
 During baseline testing, resting energy expenditure was measured using indirect 
calorimetry (ParvoMedics TrueOne® 2400) and physical activity energy expenditure was 
measured with a BodyMedia® armband (BodyMedia, Inc). The sum of these two 
measurements was used as an estimate of total daily energy expenditure (TDEE) and the 
participants were provided with this much energy during the day of testing. For all meals, 
the percent of energy from each macronutrient was ~50% carbohydrate, 35% fat, and 
15% protein. The breakfast meal was 2,448 kj, the lunch meal was 2,439 kj, and the 
dinner meal was a spaghetti dinner with 1.5 g of acetaminophen (to assess gastric 
emptying). The energy content of dinner was calculated by subtracting 4,962 kj (from 
breakfast and lunch meals) from the estimated TDEE for each participant.  
Indirect Calorimetry, Heart Rate, Ratings of Perceived Exertion, and Well-being 
 Indirect calorimetry was used to measure energy expenditure and substrate 
oxidation during the time frame when RE was performed and for ~15-30 min starting 
~3.5 h after dinner. Ratings of perceived exertion were measured at the end of every RE 
set using the BORG 6-20 scale. Subjective well-being was assessed using a 100-mm 
visual analog scale after every blood draw to determine how RE made the participants 
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feel. The question was worded “How strong is your overall feeling of well-being 
(pleasure)” and the participants marked a single horizontal line through the vertical line 
on the scale in-between the anchors “not at all” and “extremely”.  
Blood Collection  
 
 Blood samples were taken every 5-10 min during the first 3.7 h of testing and 
every 30 min during the last 2 h. Blood samples were transferred immediately into chilled 
EDTA tubes either pretreated with Aprotinin (ThermoFisher Scientific, Inc.) only (for 
TAG samples), chilled EDTA tubes pretreated with dipeptidyl peptidase-4 inhibitor 
(Millipore Corp.), Pefabloc® SC (DSM Nutritional Products AG), and Aprotinin (for 
hormone, glucose, and FFA analysis), or EDTA tubes not treated with any protease 
inhibitors (for acetaminophen assay). Blood was separated by centrifugation using an 
Eppendorf 5702R centrifuge at 3,000 RPM for 10 min at 4°C, and then frozen at -80˚ C 
until analysis.  
Separation of Lipoprotein Species 
 
 Separation of plasma chylomicron (Sf > 400), VLDL-1 (Sf 60-400), and VLDL-2 
(Sf 20-60) was performed using density gradient ultracentrifugation, as described by 
Karpe et al. [28], but with minor modification. KBr (0.1 g) was mixed into 1 mL of fresh 
plasma to bring the density up to ~1.1 g/L in a polyallomer ultracentrifuge tube (14 x 89 
mm. tube, Beckman Coulter, Inc.). Next, a density gradient consisting of 3 ml of KBr salt 
solution (1.1 g/l), 4 ml of NaCl solution (1.065 g/l), 3 ml of KBr solution (density 1.020 
g/l), and 1 ml of NaCl solution (density 1.006 g/l) was layered above the plasma. 
Ultracentrifugation was performed using a TH-641 (ThermoFisher Scientific, Inc.) 
swinging bucket rotor at 40,000 RPM and 10° C. For the separation of each lipoprotein 
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species, consecutive ultracentrifugations of 32 min (chylomicrons), 3 h and 28 min 
(VLDL-1), and 16 h (VLDL-2) were performed. After each run, the top 1 mL layer was 
carefully removed and frozen at -80°C until analysis. Before the next run, the tube was 
refilled with 1 mL of NaCl solution of density 1.006 g/l. Only five time points were 
assessed for TAG due to limited space in the ultracentrifuge.  
Biochemical Analyses 
 Whole blood glucose was assessed using a YSI 2700 Select (YSI Incorporated). 
Plasma TAG (Infinity™, ThermoFisher Scientific Inc.), free fatty acids (Wako Chemicals 
Inc.), and acetaminophen (Cambridge Life Science LTD) concentrations were determined 
using a colorimetric assay. Plasma hormone concentrations were determined using a 
MILLIPLEX magnetic bead-based immunoassay (Millipore Corp.). Hematocrit was 
measured after every blood draw and samples were corrected for plasma volume shifts. 
Plasma volume variations (ΔVP) were calculated from hematocrit variations (Ht, Ht1 = 
baseline Ht, Ht2 = after baseline Ht) using the following formula: % ΔVP = 100*[(Ht1 – 
Ht2) / (Ht2*(100-Ht1))]. Corrected plasma values were calculated using the following 
formula: Corrected Value = (Initial Value*100) / (100 - ΔVP). 
Beta-cell function 
 
 Model based beta-cell function parameters (beta-cell glucose sensitivity, 
potentiation factor ratio, and rate sensitivity) were calculated using a mathematical model 
developed by Mari et al. [29, 30]. Briefly, beta-cell glucose sensitivity is the slope of the 
dose response relation between insulin secretion, glucose concentration, and the 
potentiation factor. The potentiation factor ratio is the ratio between potentiation at the 
end of the dinner meal (220-240 min) and the initial value (0-20 min). Rate sensitivity 
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represents the enhancement of insulin secretion proportional to the rate of change of 
plasma glucose. Insulin secretion rates (ISR) used in the model were calculated by 
deconvoluting c–peptide concentrations [31].  
Calculations 
 Postprandial responses were quantified using incremental area under the curve 
(iAUC) [32]. Gastric emptying was quantified using the acetaminophen iAUC. Insulin 
clearance was calculated as the molar ratio of insulin to c-peptide at each time point as a 
percent ((1-[insulin/c-peptide pmol/L])*100). The change in glucose and TAG iAUC was 
calculated by subtracting the iAUC during the NoRE trial from the iAUC during either 
the M→RE or RE→M trial. Glycemic variability was calculated using standard deviation 
and continuous overall net glycemic action (CONGA-1, -2, and -4) [33].   
Statistical Analysis 
 
 Statistical analyses were performed using the Statistical Package for the Social 
Sciences statistical software, version 18.0 (IBM Inc.). A paired samples t-test was used to 
compare metabolic, heart rate, and perceived exertion data between trials. A repeated 
measures ANOVA with follow-up Bonferroni adjusted post hoc t-tests was used to 
determine specific differences between iAUC values. Alpha was set at P ≤ 0.05. All 
values are reported as means ± S.E.M. unless otherwise denoted.  
Results 
 
Participants 
 
 Thirteen obese men and women with type 2 diabetes completed this study (Table 
1). The participants were weight stable while enrolled in this study.  
Metabolic and Perceived Exertion Data During Exercise and Post Dinner   
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 The average heart rate was 4 beats per minute higher (P<0.05) during M→RE 
compared to RE→M, while all other variables were similar (Table 2, P>0.05). 
Postprandial energy expenditure and substrate oxidation ~3.5-4 h after dinner was not 
significantly different between trials (Table 3, P>0.05).    
Glucose, Triacylglycerol, and FFA Responses 
 
 The pre-dinner glucose iAUC was significantly lower (P<0.05) during RE→M 
compared to NoRE and M→RE (Figure 1B). The postprandial glucose iAUC was 
reduced by 30% and 18% during M→RE and RE→M, respectively, compared to NoRE 
(both P<0.05), with no difference between exercise trials (Figure 1C). During M→RE, 
the postprandial 4 h total TAG iAUC was reduced by ~92% (P<0.05) compared to NoRE 
and RE→M (Figure 2B), an effect due to reduced VLDL-1 TAG concentrations (Figure 
3D). Neither chylomicron nor VLDL-2 TAG concentrations were different between trials 
(P>0.05). The rise in pre-meal FFA concentrations was significantly attenuated (P<0.05) 
during RE→M compared to NoRE and M→RE (Figure 4B). Similarly, the drop in 
postprandial FFA concentrations was significantly less (P<0.05) during RE→M 
compared to NoRE and M→RE (Figure 4C). 
Pancreatic and Gut Hormone Responses 
 
 Pre-dinner insulin concentrations were not different between trials, but the 
postprandial insulin iAUC was 39% and 31% lower (P<0.05) during M→RE and 
RE→M, respectively, compared to NoRE (Figure 5C). The pre-dinner c-peptide iAUC 
was ~2.7 fold lower (P<0.05) during RE→M compared to M→RE and NoRE (Figure 
5E). The postprandial c-peptide iAUC was 45% lower (P<0.05) during M→RE 
compared to NoRE (Figure 5F). Pre-meal glucagon responses were not different between 
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trials but the postprandial glucagon iAUC dropped significantly more (P<0.05) during 
RE→M compared to the other trials because it was higher at the start of the meal (Figure 
5I). Neither pre-meal nor postprandial GIP concentrations were significantly different 
between trials (Figure 6A). During M→RE, the postprandial GLP-1 iAUC was 50% and 
49% lower (P<0.05) compared to RE→M and NoRE, respectfully (Figure 6F). 
Insulin Kinetics, Beta-cell Function, and Gastric Emptying 
 The postprandial ISR iAUC was 40% lower (P<0.05) during the M→RE trial 
compared to the NoRE trial (Figure 7B). The postprandial insulin clearance iAUC was 
nearly 3 fold and 2 fold greater (P<0.05) during RE→M and M→RE, respectfully, 
compared to NoRE and nearly 2 fold greater (P<0.05) during RE→M compared to 
M→RE (Figure 7D). There were no significant differences (P>0.05) in gastric emptying, 
beta-cell glucose sensitivity, rate sensitivity, or the potentiation factor ratio between trials 
(Table 4).  
Glycemic Variability, Nocturnal and Morning Glycaemic Control, and Insulin Sensitivity 
 Glycaemic variability over the 24 h period between the beginning of lunch on day 
2 and day 3 of each trial was not significantly different (P>0.05) between trials (Table 5). 
Furthermore, nocturnal or morning glycaemic control (Table 6), fasting glucose, insulin, 
c-peptide, insulin clearance, HOMA-IR, QUICKI, and TAG (Table 7) were not different 
between trials the next morning (P>0.05).  
Subjective Well-being  
 
 Baseline well-being was significantly different between trials (P<0.05), thus to 
better illustrate the change in well-being, change scores were used. The pre-meal 
subjective well-being iAUC was significantly greater during RE→M compared to NoRE 
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(P<0.05) and tended to be greater (P=0.064) compared to M→RE (Figure 8B). The 
postprandial well-being iAUC was significantly greater (P<0.05) with RE compared to 
NoRE, independent of RE timing (Figure 8D).   
Discussion 
 
With a push toward personalized medicine, knowledge of the best time to perform 
RE around dinner will provide health care professionals with a better idea of how to 
personalize RE prescription to optimize its metabolic health benefits. Thus, the 
overarching goal of this project was to identify the best time, either before or after dinner, 
to perform RE to lower postprandial glucose and TAG concentrations, two important 
cardiovascular disease risk factors in obese patients with type-2 diabetes. The key 
findings of this study are: 1) Both pre- and post-dinner RE reduces postprandial glucose 
concentrations, while only post-dinner RE reduces both postprandial glucose and TAG 
concentrations, 2) Both pre- and post-dinner RE reduces insulin concentrations,  but via 
different mechanisms as pre-dinner RE enhances insulin clearance, whereas post-dinner 
RE reduces pancreatic insulin secretion and enhances insulin clearance, 3) Post-dinner 
RE reduces postprandial GLP-1 concentrations while pre-dinner RE does not, 4) Pre-
dinner RE reduces pre-dinner FFA concentrations and attenuates the decline in 
postprandial FFA concentrations, 5) Gastric emptying, beta-cell function, postprandial 
substrate oxidation, GIP concentrations, nocturnal and postprandial glucose 
concentrations or insulin sensitivity the following morning are not altered by pre- or post-
dinner RE, and 6) RE improved well-being when performed before or after dinner. Taken 
together, post-dinner RE improves postprandial metabolic risk factors better than pre-
dinner RE in obese patients with type-2 diabetes and these benefits are short lived and do 
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not last into the overnight period or into the next day. Importantly, RE improved well-
being, making it a feasible option in this population. 
 Previous research is mixed as two studies have shown that acute RE prior to a 
meal (s) improves glycaemic control [19] [18], but two other studies showed acute RE 
does not improve glycaemic control in patients with type-2 diabetes [24, 25]. In the 
current study both pre- and post-dinner RE glycaemic control compared to NoRE, but 
neither RE time was significantly better compared to the other at doing so. With pre-
dinner RE, postprandial glucose concentrations were lower from ~1-3 h after the meal 
compared to NoRE. During post-dinner RE, glucose concentrations were lower during 
exercise from ~45 min – 1.5 h after the meal, and rebounded at the cessation of exercise 
to NoRE levels. These drastic differences in glucose responses suggest different glucose 
lowering mechanisms may be at play depending on RE timing. Previous research has 
shown acute RE increases skeletal muscle GLUT 4 protein (independent of insulin) up to 
3.5 h after exercise [34] and insulin sensitivity up to 24 h post RE [35, 36], therefore 
during the pre-dinner RE trial, insulin independent glucose uptake and insulin action 
could have been increased prior to the meal in the previously exercised skeletal muscle 
and the liver, thus increasing postprandial skeletal muscle glucose uptake and reducing 
hepatic glucose output. During the post-dinner RE trial, elevated insulin concentrations 
due to the meal as well as the skeletal muscle contractions probably worked 
synergistically to increase skeletal muscle blood glucose uptake, as has been shown with 
aerobic exercise [9, 37]. Interestingly, once the post-dinner RE session was over, blood 
glucose concentrations rebounded and were similar to those during the NoRE trial. This 
rebound in glucose may have been due to a simultaneous reduction in skeletal muscle 
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glucose uptake at the cessation of exercise and a transient increase in hepatic glucose 
output, which has been shown to occur with postprandial aerobic exercise [9]. The 
improvements in glycaemia in the current study were short-lived and did not extend into 
the nocturnal period or into the morning period the next day, which suggests that daily 
exercise is required to maintain improvements in glycaemia.      
 For the first time, this study shows that post-dinner RE lowers postprandial TAG 
concentrations, whereas pre-dinner RE does not. The available data with aerobic exercise 
is similar as two studies have shown prior aerobic exercise performed the day prior to the 
test meal does not alter postprandial TAG concentrations [21, 23], while in another study 
post-meal aerobic exercise reduced postprandial TAG concentrations compared to no 
exercise [20]. The majority of TAG in circulation originates from either exogenous 
sources and is in the form of chylomicron particles or endogenous sources from the liver 
and is in the form of VLDL-TAG [38]. We attempted to establish whether chylomicrons 
or VLDL-TAG were modified by RE timing, and observed that neither pre-meal nor 
post-meal RE modified postprandial chylomicron or VLDL-2 TAG particles. Instead, the 
reduction in postprandial TAG concentrations with post-dinner RE was mediated by 
reduced VLDL-1 TAG concentrations. Although not possible to determine from the data, 
the mechanism(s) for the reduction in VLDL-1 TAG with RE could have been mediated 
by enhanced hydrolysis of TAG by lipoprotein lipase in skeletal muscle and/or by 
reduced hepatic VLDL-1 TAG secretion [38].      
 In the current study, both pre- and post-dinner RE reduced postprandial insulin 
concentrations, a finding that is in agreement with other work [24] but with differing 
physiological mechanisms. With pre-dinner RE, the reduction in postprandial insulin 
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concentrations was mediated by enhanced insulin clearance, and this has been shown 
before [24]. Although pre-dinner RE reduced glucose concentrations, this was not 
associated with reduced insulin secretion, possibly because the insulin potentiating 
hormones GLP-1 or GIP were not reduced. This finding is similar to another study in 
which pre-meal aerobic exercise did not alter postprandial GLP-1 or GIP responses in 
type 2 diabetic patients [39]. On the contrary, during post-dinner RE the reduction in 
insulin concentrations was mediated by both increased insulin clearance and reduced 
insulin secretion, although the increase in insulin clearance was not as great as compared 
to the pre-dinner RE trial. Lower postprandial insulin secretion with post-dinner RE 
could have been mediated by reduced GLP-1 and glucose concentrations, and not by 
changes in GIP or beta-cell function. The mechanism by which RE increases insulin 
clearance could potentially be due to increased skeletal muscle and/or liver blood flow. 
Increased blood flow in these tissues may increase blood flow through previously non-
flowing capillaries, allowing more insulin to be exposed to and bind to the insulin 
receptor, internalized, and degraded. This hypothesis is supported by the work of Philips 
et al. [40] who showed that prior RE enhanced postprandial leg blood flow responses, 
compared to no exercise. Another possibility may by that RE reduced portal vein glucose 
and/or FFA concentrations. Given that glucose and FFA have been shown to 
independently and synergistically impair insulin binding to receptors [41], it is possible 
that a RE induced reduction in these substrates in the portal vein allowed more hepatic 
insulin clearance.    
 In conclusion, acute post-dinner RE improves postprandial metabolic risk factors 
better than pre-dinner RE in obese patients with type-2 diabetes. Future studies are 
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needed to determine if long-term post-meal exercise training would better reduce 
cardiovascular disease more so than pre-meal exercise. 
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Tables 
 
 
Table 1. Patient Characteristics (N = 13, 5 Males) 
Age (yr)   48.5 ± 11.9 
Height (m)   1.67 ± 0.11 
Weight (kg) 103.2 ± 22.8  
Body mass index (kg/m2)   36.7 ± 5.3 
Body fat percent   39.5 ± 8.6 
Fasting Glucose (mmol/L)      8.2 ± 2.3 
Fasting Hemoglobin A1c (% [mmol/mol])     7.2 ± 1.1 [55] 
Diagnosed with Type 2 Diabetes (yr)      3.7 ± 3.9  
Patients with antidiabetes medication use, n          12 
Values are means ± SD  
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Table 2. Metabolic data and rating of perceived exertion during resistance exercise session.  
 RE→M NoRE-1 M→RE NoRE-1 
Time (min)      46 ± 1       46 ± 1    47 ± 1     47 ± 1 
Oxygen consumption (ml kg-1 min-1)     6.1 ± 0.4      2.9 ± 0.1*   6.0 ± 0.3    2.9 ± 0.1* 
Energy Expenditure (Gross kj)    586 ± 59    264 ± 13*  590 ± 59     276 ± 21* 
Respiratory Exchange Ratio   1.00 ± 0.01   0.83 ± 0.01* 1.00 ± 0.01  0.87 ± 0.01*† 
Heart Rate (bpm)    106 ± 4   110 ± 4**  
Average RPE (BORG 6-20 scale)      12 ± 1      12 ± 1  
Values are means ± S.E.M.   
The data under NoRE-1 is during the same time frame (i.e. before dinner) as 
RE→M but during the NoRE trial, while the data under NoRE-2 is during the same 
time frame (i.e. after dinner) as M→RE but during the NoRE trial.    
*P < 0.05 compared to RE→M or M→RE. 
**P < 0.05 compared to heart rate during the RE→M trial.   
†P < 0.05 compared to NoRE-1. 
For the variables time, oxygen consumption, energy expenditure, respiratory 
exchange ratio, and heart rate, only data for N = 12 is reported. For RPE, data for N 
= 13 is reported.  
 
Table 3. Energy Expenditure and Substrate Oxidation ~3.5 - 4 h After Dinner Meal 
 Energy Expenditure (kj min-1) RER 
NoRE 5.9 ± 0.4 0.85 ± 0.01 
RE→M 5.9 ± 0.4 0.83 ± 0.01 
M→RE 6.3 ± 0.4 0.83 ± 0.01 
Values are means ± S.E.M. 
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Table 5. Average Blood Glucose and Glycemic Variability Over 24 h  
 NoRE RE-M M-RE 
Average Blood Glucose 
(mmol/L) 
          7.8 ± 0.4            7.2 ± 0.4         7.8 ± 0.6 
Standard Deviation           1.8 ± 0.2            1.7 ± 0.2       2.1 ± 0.2  
CONGA-1           6.8 ± 0.4             6.3 ± 0.3       6.7 ± 0.5  
CONGA-2           6.1 ± 0.4            5.7 ± 0.3       6.0 ± 0.5 
CONGA-4           5.7 ± 0.4            5.5 ± 0.3       5.4 ± 0.5 
Values are means ± S.E.M.  
Data is for N = 11 participants as 2 participants had missing data so they were excluded. 
 
 
 
 
Table 6. Nocturnal and Post-Breakfast Glucose Responses 
             NoRE RE→M M→RE 
Nocturnal Glucose Responses (12-6 a.m.)   
  Average Blood Glucose (mmol/L)       6.3 ± 0.5  5.9 ± 0.4   6.4 ± 0.6 
  Time Hyperglycemic (min) 
  (Blood Glucose > 10 mmol/L)    0.4 ± 0.6  2.7 ± 3.9 14.6 ± 10.6 
  Time Hypoglycemic (min) 
  (Blood Glucose < 3.9 mmol/L)    26.5 ± 30.5    17.7 ± 7.8   6.9 ± 3.7 
Morning Glucose Responses    
  Average Morning Blood Glucose 
(mmol/L)    8.9 ± 0.6   8.7 ± 0.7   9.1 ± 0.9 
  Breakfast 4 h iAUC (mmol/L per 4 h)    72 ± 17    83 ± 23     75 ± 22  
  Time Hyperglycemic (min) 
  (Blood Glucose > 10 mg/dL)    80.8 ± 22.7  43.3 ± 19.0 66.3 ± 27.5 
  Time Hypoglycemic (min) 
  (Blood Glucose < 3.9 mg/dL)    0 0 0 
Values are means ± S.E.M.  
Table 4. Beta-cell Function Parameters and Gastric Emptying 
 NoRE RE→M M→RE 
Beta-cell glucose 
sensitivity ((pmol/(min m2 
mM)) 
39 ± 5 50 ± 8           50 ± 9 
Rate Sensitivity  
(pmol/(m2 mM)) 306 ± 93   402 ± 141         307 ± 86 
Potentiation Factor Ratio  
(fold)   1.28 ± 0.14   0.99 ± 0.08 0.92 ± 0.10 
Acetaminophen iAUC 
(µmol/L)      17,777 ± 1,866  15,493 ± 1,792     19,001 ± 1,626 
Values are means ± S.E.M.  
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The data for the nocturnal glucose response is for N = 13 while the data for the morning 
glucose responses is for N = 12.  
 
 
 
 
 
Figures  
Figure 1. Glucose Responses During Testing 
 
 
Table 7. Morning Fasting Measures The Day After Testing In The Lab   
 NoRE RE→M M→RE 
Blood Glucose (mmol/L)     6.7 ± 0.4     6.7 ± 0.3        6.7 ± 0.6 
Insulin (pmol/L)        290 ± 43        256 ± 37       301 ± 53 
C-Peptide (pmol/L)      1537 ± 181      1378 ± 113     1465 ± 194 
Insulin Clearance (%)          81 ± 2           82 ± 2         80 ± 2 
HOMA-IR      12.58 ± 1.98      10.98 ± 1.77    12.05 ± 1.92 
QUICKI       0.28 ± 0.01        0.28 ± 0.01      0.28 ± 0.05 
Triacylglycerol (mmol/L)         1.5 ± 0.2         1.5 ± 0.2        1.6 ± 0.2 
Values are means ± S.E.M. 
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Figure 2. Total Triacylglycerol Responses During Testing 
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Figure 3. Exogenous and Endogenous Triacylglycerol Responses During Testing 
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Figure 4. Free Fatty Acid Responses During Testing 
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Figure 5. Pancreatic Hormone Responses During Testing 
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Figure 6. Gut Hormone Responses During Testing 
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Figure 7. Insulin Kinetics During Testing 
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Figure 8. Subjective Well-being During Testing 
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